<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PPAR Res</journal-id><journal-id journal-id-type="iso-abbrev">PPAR Res</journal-id><journal-id journal-id-type="publisher-id">PPAR</journal-id><journal-title-group><journal-title>PPAR Research</journal-title></journal-title-group><issn pub-type="ppub">1687-4757</issn><issn pub-type="epub">1687-4765</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5828371</article-id><article-id pub-id-type="doi">10.1155/2018/6727421</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Peroxisome Proliferator-Activated Receptor <italic>&#x003b3;</italic> and PGC-1<italic>&#x003b1;</italic> in Cancer: Dual Actions as Tumor Promoter and Suppressor</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6197-1383</contrib-id><name><surname>Yun</surname><given-names>Seong-Hoon</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4098-9859</contrib-id><name><surname>Han</surname><given-names>Sang-Heum</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6156-8201</contrib-id><name><surname>Park</surname><given-names>Joo-In</given-names></name><email>jipark@dau.ac.kr</email><xref ref-type="aff" rid="I1"/></contrib></contrib-group><aff id="I1">Department of Biochemistry, Dong-A University College of Medicine, Busan, Republic of Korea</aff><author-notes><fn fn-type="other"><p>Academic Editor: Annamaria Cimini</p></fn></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>21</day><month>1</month><year>2018</year></pub-date><volume>2018</volume><elocation-id>6727421</elocation-id><history><date date-type="received"><day>7</day><month>9</month><year>2017</year></date><date date-type="rev-recd"><day>16</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>19</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Seong-Hoon Yun et al.</copyright-statement><copyright-year>2018</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> (PPAR<italic>&#x003b3;</italic>) is part of a nuclear receptor superfamily that regulates gene expression involved in cell differentiation, proliferation, immune/inflammation response, and lipid metabolism. PPAR<italic>&#x003b3;</italic> coactivator-1<italic>&#x003b1;</italic> (PGC-1<italic>&#x003b1;</italic>), initially identified as a PPAR<italic>&#x003b3;</italic>-interacting protein, is an important regulator of diverse metabolic pathways, such as oxidative metabolism and energy homeostasis. The role of PGC-1<italic>&#x003b1;</italic> in diabetes, neurodegeneration, and cardiovascular disease is particularly well known. PGC-1<italic>&#x003b1;</italic> is also now known to play important roles in cancer, independent of the role of PPAR<italic>&#x003b3;</italic> in cancer. Though many researchers have studied the expression and clinical implications of PPAR<italic>&#x003b3;</italic> and PGC-1<italic>&#x003b1;</italic> in cancer, there are still many controversies about the role of PPAR<italic>&#x003b3;</italic> and PGC-1<italic>&#x003b1;</italic> in cancer. This review examines and summarizes some recent data on the role and action mechanisms of PPAR<italic>&#x003b3;</italic> and PGC-1<italic>&#x003b1;</italic> in cancer, respectively, particularly the recent progress in understanding the role of PPAR<italic>&#x003b3;</italic> in several cancers since our review was published in 2012. </p></abstract><funding-group><award-group><funding-source>Ministry of Science, ICT and Future Planning</funding-source><award-id>2017R1A2B4011428</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> (PPAR<italic>&#x003b3;</italic>) belongs to a nuclear hormone receptor superfamily that regulates the expression of genes involved in cell differentiation, proliferation, the immune/inflammation response, and lipid metabolism [<xref rid="B1" ref-type="bibr">1</xref>]. Ligand binding and activation of PPAR<italic>&#x003b3;</italic> result in heterodimer formation with the retinoid X receptor (RXR) and binding to a PPAR response element (PPRE) to regulate the transcription of numerous target genes [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>]. PPAR<italic>&#x003b3;</italic> consists of a ligand-independent transcriptional activation domain, DNA binding domain (DBD), hinge region for cofactor docking, and ligand binding domain (LBD) (<xref ref-type="fig" rid="fig1">Figure 1(a)</xref>). Two PPAR<italic>&#x003b3;</italic> isoforms are known, PPAR<italic>&#x003b3;</italic>1 and PPAR<italic>&#x003b3;</italic>2 [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>]. PPAR<italic>&#x003b3;</italic>2, which is generated by alternative splicing, contains an additional 28 amino acids in mice and 30 amino acids in humans, at the N-terminus compared to PPAR<italic>&#x003b3;</italic>1. PPAR<italic>&#x003b3;</italic>2 is expressed selectively in adipose tissue and plays an important role in adipocyte differentiation, lipid storage in white adipose tissue, and energy dissipation in brown adipose tissue [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B6" ref-type="bibr">6</xref>]. PPAR<italic>&#x003b3;</italic>1 is expressed in the colon, immune system, and hematopoietic cells and plays an important role in the control of inflammation, macrophage maturation, and embryo implantation. PPAR<italic>&#x003b3;</italic>1 is a molecular target of antidiabetic thiazolidinediones [<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>]. Our previous review summarized the role and action mechanisms of PPAR<italic>&#x003b3;</italic> in colorectal cancer [<xref rid="B8" ref-type="bibr">8</xref>], but the role of PPAR<italic>&#x003b3;</italic> in cancer is still debated. Thus, this review updates the progress in understanding the role and molecular mechanisms of PPAR<italic>&#x003b3;</italic> in cancer.</p><p>The PPAR<italic>&#x003b3;</italic> coactivator-1 (PGC-1) family is composed of PGC-1<italic>&#x003b1;</italic>, PGC-1<italic>&#x003b2;</italic>, and PGC-1-related coactivator (PRC). PGC-1<italic>&#x003b1;</italic> was initially identified as a transcriptional coactivator involved in mitochondrial function and thermogenesis in brown fat [<xref rid="B9" ref-type="bibr">9</xref>]. PGC-1<italic>&#x003b2;</italic> and PRC were discovered in sequence homology searches [<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B13" ref-type="bibr">13</xref>]. The PGC-1 family members have similar activity to increase mitochondrial function when overexpressed and have a related modular structure (<xref ref-type="fig" rid="fig1">Figure 1(b)</xref>). The most common functional domains are shared between PGC-1<italic>&#x003b1;</italic> and PGC-1<italic>&#x003b2;</italic>. The N-terminal activation domain interacts with several transcriptional coactivators, including p300 and steroid receptor coactivator-1 (SRC-1). A domain involved in inhibition of PGC-1 activity is located adjacent to the N-terminal region. Through several LXXLL motifs, the N-terminal half of PGC-1 interacts with many transcription factors, whereas the C-terminal end of PGC-1 interacts with the TRAP/DRIP/Mediator complex. PGC-1<italic>&#x003b1;</italic> has a Ser/Arg-rich domain and RNA binding motif that plays an important role in mRNA splicing [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>]. Because PGC-1<italic>&#x003b1;</italic> was described initially as a PPAR<italic>&#x003b3;</italic> interacting protein, some investigators recently studied the expression and clinical significance of PGC-1<italic>&#x003b1;</italic> in cancer [<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>]. However, the expression and the roles of PGC-1<italic>&#x003b1;</italic> in cancer were not significantly related to the expression of PPAR<italic>&#x003b3;</italic>. In addition, controversies still exist whether PGC-1<italic>&#x003b1;</italic> acts as a tumor promoter or a tumor suppressor in cancer. This review focuses on the expression and actions of PGC-1<italic>&#x003b1;</italic> in order to understand the clinical significance of PGC-1<italic>&#x003b1;</italic> expression in cancer.</p></sec><sec id="sec2"><title>2. The Role and Action Mechanisms of PPAR<bold><italic>&#x003b3;</italic></bold> in Cancer</title><p>PPAR<italic>&#x003b3;</italic> is expressed in various malignant tissues, including bladder, colon, prostate, and breast cancer [<xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B22" ref-type="bibr">22</xref>]. Natural ligands that activate PPAR<italic>&#x003b3;</italic> include long-chain polyunsaturated fatty acids, eicosanoids, components of oxidized low density lipoproteins (oxLDLs), and 15-deoxy-&#x00394;<sup>12,14</sup>-prostaglandin J<sub>2</sub> (15d-PGJ<sub>2</sub>) [<xref rid="B23" ref-type="bibr">23</xref>]. Synthetic ligands include the antidiabetic thiazolidinedione (TZD) class of drugs [<xref rid="B23" ref-type="bibr">23</xref>]. An increasing number of studies have focused on the effect of PPAR<italic>&#x003b3;</italic> in cancer using natural and synthetic ligands for PPAR<italic>&#x003b3;</italic> and overexpression experiments. However, the role of PPAR<italic>&#x003b3;</italic> in cancer is still debated. Thus, this review updates the role and action mechanisms of PPAR<italic>&#x003b3;</italic> in cancer since our review published in 2012.</p><sec id="sec2.1"><title>2.1. PPAR<italic>&#x003b3;</italic> as a Tumor Suppressor in Cancer</title><p>Our previous review summarized that PPAR<italic>&#x003b3;</italic> inhibits cell proliferation and induces apoptosis through the upregulation of Phosphatase and Tensin Homolog (PTEN), downregulation of survivin, downregulation of X-linked inhibitor of apoptosis (XIAP), suppression of NF-<italic>&#x003ba;</italic>B and glycogen synthase kinase (GSK)-3<italic>&#x003b2;</italic>, upregulation of cyclin-dependent kinase (CDK) inhibitors, downregulation of CDK and cyclin D1, downregulation of COX-2, upregulation of Kr&#x000fc;ppel-Like Factor 4 (KLF4), upregulation of Bax, downregulation of Bcl-2, and inhibition of telomerase activity and hTERT expression through modulation of the Myc/Mad/Max network [<xref rid="B8" ref-type="bibr">8</xref>]. This review briefly describes and summarizes new molecular mechanisms of PPAR<italic>&#x003b3;</italic>-related tumor suppression since 2012 (<xref ref-type="table" rid="tab1">Table 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>Understanding the role of PPAR<italic>&#x003b3;</italic> in cancer was improved by developing new synthetic and natural ligands of PPAR<italic>&#x003b3;</italic> and performing overexpression and knockdown experiments. PPAR<italic>&#x003b3;</italic> agonist troglitazone inhibits colon cancer cell growth through the inactivation of NF-<italic>&#x003ba;</italic>B by suppressing GSK-3<italic>&#x003b2;</italic> activity [<xref rid="B24" ref-type="bibr">24</xref>]. Emerging data suggest that PPAR<italic>&#x003b3;</italic> acts as a tumor suppressor by inactivating NF-<italic>&#x003ba;</italic>B through different mechanisms. For example, Lee et al. demonstrated that 4-O-methylhonokiol (MH), a PPAR<italic>&#x003b3;</italic> agonist, has antitumor activity in prostate cancer through increased PPAR<italic>&#x003b3;</italic> activity and p21-mediated suppression of NF-<italic>&#x003ba;</italic>B activity as observed by the loss of MH-induced growth inhibition and NF-<italic>&#x003ba;</italic>B inhibition in a p21 siRNA knockdown experiment [<xref rid="B25" ref-type="bibr">25</xref>]. In addition, overexpression of PPAR<italic>&#x003b3;</italic> was shown to inhibit cell proliferation and tumor growth via degradation of NF-<italic>&#x003ba;</italic>B by acting as an E3 ligase [<xref rid="B26" ref-type="bibr">26</xref>]. Hou et al. demonstrated that PPAR<italic>&#x003b3;</italic> inhibits mucin 1- (MUC1-) C-mediated cell proliferation via MUC1-C ubiquitination and degradation [<xref rid="B27" ref-type="bibr">27</xref>]. MUC1-C is known as an oncoprotein and interacts with I<italic>&#x003ba;</italic>B kinase, NF-<italic>&#x003ba;</italic>B/p65, and signal transducer and activator of transcription factor 3 (Stat3), p53, or BAX in order to activate the downstream pathway associated with tumor growth [<xref rid="B28" ref-type="bibr">47</xref>&#x02013;<xref rid="B33" ref-type="bibr">52</xref>]. Efatutazone, a third-generation PPAR<italic>&#x003b3;</italic> agonist, has been reported to inhibit esophageal squamous cell carcinoma (ESCC) cell proliferation<italic> in vitro</italic> and<italic> in vivo</italic> through increased p21Cip protein levels via inactivation of Akt [<xref rid="B34" ref-type="bibr">28</xref>].</p><p>Several recent studies have shown that PPAR<italic>&#x003b3;</italic> agonists inhibit the survival of cancer stem cells (CSCs) [<xref rid="B37" ref-type="bibr">29</xref>, <xref rid="B38" ref-type="bibr">30</xref>, <xref rid="B35" ref-type="bibr">53</xref>&#x02013;<xref rid="B39" ref-type="bibr">55</xref>]. PPAR<italic>&#x003b3;</italic> and RXR agonists were demonstrated to inhibit interleukin-6 (IL-6) promoter activity and reduce MMP-2 and MMP-9 expression and activity in tumor-associated fibroblasts [<xref rid="B37" ref-type="bibr">29</xref>]. Prost et al. demonstrated that pioglitazone, a PPAR<italic>&#x003b3;</italic> agonist, eradicates CSCs via the decreased expression of STAT5 and HIF-2<italic>&#x003b1;</italic> in chronic myeloid leukemia [<xref rid="B38" ref-type="bibr">30</xref>].</p><p>The Wnt/<italic>&#x003b2;</italic>-catenin signaling pathway plays an important role in the occurrence and development of cancer [<xref rid="B40" ref-type="bibr">56</xref>, <xref rid="B41" ref-type="bibr">57</xref>]. Guo et al. reported that PPAR<italic>&#x003b3;</italic> overexpression inhibits the proliferation and migration of gastric cancer cells through downregulation of telomerase reverse transcriptase (TERT) and enabled homolog (ENAH) via inhibition of <italic>&#x003b2;</italic>-catenin [<xref rid="B42" ref-type="bibr">31</xref>]. Mammalian enabled (Mena), encoded by<italic> ENAH</italic>, is an actin-regulatory protein involved in controlling cell motility and cell-cell adhesion, which are important for the development of metastatic potential [<xref rid="B43" ref-type="bibr">58</xref>].<italic> TERT</italic> and<italic> ENAH </italic>are new targets of the Wnt/<italic>&#x003b2;</italic>-catenin signaling pathway [<xref rid="B44" ref-type="bibr">59</xref>, <xref rid="B45" ref-type="bibr">60</xref>]. Recently, activation of canonical Wnt signaling was reported to directly act on aerobic glycolysis and increase vessel formation in colon cancer through the Wnt target gene pyruvate dehydrogenase kinase 1<italic> (PDK1)</italic> [<xref rid="B46" ref-type="bibr">61</xref>]. Via PDK1 activation, pyruvate is converted into acetyl-CoA, which enters the TCA cycle and is converted into citrate, which stimulates protein synthesis. Accumulation of metabolic intermediates (such as aspartate, glycine, serine, and ribose) in cells promotes de novo nucleotide synthesis, contributing to growth and proliferation [<xref rid="B47" ref-type="bibr">62</xref>]. In addition, blocking the Wnt pathway decreases PDK1 expression via transcriptional regulation and inhibits<italic> in vivo</italic> tumor growth [<xref rid="B46" ref-type="bibr">61</xref>].</p><p>Pseftogas et al. reported that PPAR<italic>&#x003b3;</italic> activation has a tumor suppressive effect by upregulating the expression of tumor suppressor<italic> Cyld</italic>, as the<italic> Cyld</italic> promoter has PPAR<italic>&#x003b3;</italic> binding sites [<xref rid="B48" ref-type="bibr">32</xref>].<italic> Cyld</italic> was identified as a tumor suppressor gene that is causally associated with the development of inherited cylindromas [<xref rid="B49" ref-type="bibr">63</xref>]. The gene encodes a protein (CYLD) possessing a carboxyl-terminal ubiquitin-specific protease domain that selectively hydrolyzes K63- and M1-linked polyubiquitin chains [<xref rid="B50" ref-type="bibr">64</xref>]. A number of studies have suggested a role for CYLD in the growth suppression of different types of cancer cells, such as colon, hepatocellular, lung, melanoma, and breast cancer (reviewed in [<xref rid="B51" ref-type="bibr">65</xref>]). CYLD can inhibit several growth and antiapoptotic signaling pathways, including the NF-<italic>&#x003ba;</italic>B, JNK, p38, Wnt, Akt, and Notch pathways [<xref rid="B51" ref-type="bibr">65</xref>].</p><p>Rovito et al. demonstrated that PPAR<italic>&#x003b3;</italic> activation downregulates CXCR4 gene expression through recruitment of the silencing mediator of retinoid and thyroid hormone receptor (SMRT) corepressor to PPRE within the CXCR4 promoter and then inhibits breast cancer cell migration and invasion [<xref rid="B52" ref-type="bibr">33</xref>]. CXCR4, a seven-transmembrane G-protein-coupled receptor for stromal-cell derived factor-1<italic>&#x003b1;</italic> (SDF-1<italic>&#x003b1;</italic>), has been shown to be expressed in human breast cancer cells, and activation of the SDF-1<italic>&#x003b1;</italic>/CXCR4 axis is important in breast cancer migration and metastasis [<xref rid="B53" ref-type="bibr">66</xref>, <xref rid="B54" ref-type="bibr">67</xref>].</p></sec><sec id="sec2.2"><title>2.2. PPAR<italic>&#x003b3;</italic> as a Tumor Promoter in Cancer</title><p>Our previous review described that PPAR<italic>&#x003b3;</italic> has tumor-promoting activity through the upregulation of <italic>&#x003b2;</italic>-catenin and c-Myc expression, upregulation of COX-2, upregulation of the expression of vascular endothelial growth factor (VEGF) and VEGF receptors, and upregulation of MMP-1 [<xref rid="B8" ref-type="bibr">8</xref>]. This review briefly introduces the action mechanisms of PPAR<italic>&#x003b3;</italic> as a tumor promoter (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>Recently, increasing evidence has indicated that PPAR<italic>&#x003b3;</italic> acts as a tumor promoter [<xref rid="B55" ref-type="bibr">68</xref>&#x02013;<xref rid="B74" ref-type="bibr">74</xref>]. Downregulation of PPAR<italic>&#x003b3;</italic> by siRNA knockdown or treatment with PPAR<italic>&#x003b3;</italic> antagonist GW9662 has been shown to inhibit the growth of cancer cells, suggesting a tumor-promoting effect for PPAR<italic>&#x003b3;</italic> in these cells [<xref rid="B55" ref-type="bibr">68</xref>&#x02013;<xref rid="B57" ref-type="bibr">70</xref>]. PPAR<italic>&#x003b3;</italic> was shown to protect ErbB2-positive breast cancer cells from palmitate-induced toxicity [<xref rid="B58" ref-type="bibr">75</xref>]. In addition, PPAR<italic>&#x003b3;</italic> was demonstrated to play a crucial role in the maintenance of stemness in ErbB2-positive breast cancer cells; PPAR<italic>&#x003b3;</italic> antagonist GW9662 induces apoptosis and inhibits tumorsphere formation and tumor formation through the inhibition of lipogenic genes<italic> (ACLY, MIG12, FASN, </italic>and<italic> NR1D1)</italic> and stem cell-related genes (<italic>KLF4 </italic>and<italic> ALDH</italic>) [<xref rid="B59" ref-type="bibr">71</xref>]. CSCs have been identified as subpopulations of cells within tumors that promote tumor growth and recurrence [<xref rid="B60" ref-type="bibr">76</xref>&#x02013;<xref rid="B62" ref-type="bibr">78</xref>].</p><p>Kesanakurti et al. demonstrated that PPAR<italic>&#x003b3;</italic> is involved in radiation-induced epithelial-to-mesenchymal transition (EMT) in glioma by interacting with p21-activated kinase 4 (PAK4), resulting in increased Nox1 expression and reactive oxygen species (ROS) [<xref rid="B63" ref-type="bibr">72</xref>]. EMT is a developmental transdifferentiation program facilitating the formation of highly motile cells with stem cell characteristics [<xref rid="B64" ref-type="bibr">79</xref>, <xref rid="B65" ref-type="bibr">80</xref>]. EMT is also involved in increased metastatic potential and treatment resistance in cancer [<xref rid="B66" ref-type="bibr">81</xref>, <xref rid="B67" ref-type="bibr">82</xref>]. The PAKs are a family of serine/threonine kinases involved in embryonic development, cytoskeletal remodeling, cell motility, and cell proliferation [<xref rid="B68" ref-type="bibr">83</xref>, <xref rid="B69" ref-type="bibr">84</xref>], and aberrant expression of PAK4 has been shown to promote cancer cell proliferation and invasion [<xref rid="B70" ref-type="bibr">85</xref>&#x02013;<xref rid="B72" ref-type="bibr">87</xref>].</p><p>A recent study using PPAR<italic>&#x003b3;</italic> siRNA showed that PPAR<italic>&#x003b3;</italic> suppression inhibits cell proliferation, colony formation, and tumorigenicity<italic> in vivo</italic> [<xref rid="B73" ref-type="bibr">73</xref>]. In addition, PPAR<italic>&#x003b3;</italic> upregulated VEGF expression through the binding of PPAR<italic>&#x003b3;</italic> in the promoter region of<italic> VEGF</italic> in prostate cancer cells [<xref rid="B73" ref-type="bibr">73</xref>]. Patitucci et al. demonstrated that PPAR<italic>&#x003b3;</italic> activation is involved in steatosis-associated liver cancer and provided evidence supporting the pharmacological modulation of hepatic PPAR<italic>&#x003b3;</italic> activity as a therapeutically relevant strategy in hepatic malignancy associated with activated Akt2 and PPAR<italic>&#x003b3;</italic> signaling [<xref rid="B74" ref-type="bibr">74</xref>].</p></sec></sec><sec id="sec3"><title>3. The Role and Action Mechanisms of PGC-1<bold><italic>&#x003b1;</italic></bold> in Cancer</title><p>Many studies have examined the role of PGC-1<italic>&#x003b1;</italic> in cancer by observing its expression in several cancers and performing PGC-1<italic>&#x003b1;</italic> overexpression and siRNA knockdown experiments. PGC-1<italic>&#x003b1;</italic> expression has been shown in some studies to be decreased in some types of cancer, including colon [<xref rid="B75" ref-type="bibr">88</xref>], breast [<xref rid="B76" ref-type="bibr">89</xref>], and ovarian cancer [<xref rid="B77" ref-type="bibr">41</xref>], whereas other studies have shown that PGC-1<italic>&#x003b1;</italic> expression is increased in cancer [<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B78" ref-type="bibr">90</xref>]. Even though many studies have been published, the role of PGC-1<italic>&#x003b1;</italic> in cancer is still controversial. Therefore, this review describes the role and action mechanisms of PGC-1<italic>&#x003b1;</italic> in cancer (<xref ref-type="table" rid="tab2">Table 2</xref>).</p><sec id="sec3.1"><title>3.1. Tumor-Promoting Functions of PGC-1<italic>&#x003b1;</italic></title><p>As described above, PGC-1<italic>&#x003b1;</italic> is a regulator of PPAR<italic>&#x003b3;</italic> activity. Thus, the abnormalities in PGC-1<italic>&#x003b1;</italic> expression may affect PPAR<italic>&#x003b3;</italic> function. However, there was little report supporting that PGC-1<italic>&#x003b1;</italic> expression directs PPAR<italic>&#x003b3;</italic> activity in cancer. Thus, this review focuses on the role of PGC-1<italic>&#x003b1;</italic>, independent of the role of PPAR<italic>&#x003b3;</italic> in cancer. Literature works supporting the tumor-promoting functions of PGC-1<italic>&#x003b1;</italic> have increased [<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B79" ref-type="bibr">34</xref>&#x02013;<xref rid="B88" ref-type="bibr">40</xref>, <xref rid="B96" ref-type="bibr">42</xref>, <xref rid="B86" ref-type="bibr">91</xref>&#x02013;<xref rid="B95" ref-type="bibr">93</xref>]. Shiota et al. showed that PGC-1<italic>&#x003b1;</italic> promotes cell growth through the activation of androgen receptor in prostate cancer cells by observing cell growth inhibition with PGC-1<italic>&#x003b1;</italic> knockdown experiments [<xref rid="B17" ref-type="bibr">17</xref>]. In addition, PGC-1<italic>&#x003b1;</italic> was increased in tumor samples from arsenic-induced skin cancer patients and may be associated with increased cell proliferation and enhanced mitochondrial biogenesis [<xref rid="B79" ref-type="bibr">34</xref>]. Bhalla et al. showed that PGC-1<italic>&#x003b1;</italic> promotes carcinogenesis and tumor growth through the induction of lipogenic enzymes (acetyl-CoA carboxylase and fatty acid synthase) using genetically modified PGC-1<italic>&#x003b1;</italic> mice [<xref rid="B80" ref-type="bibr">35</xref>]. That study demonstrated that PGC-1<italic>&#x003b1;</italic> knockout mice had decreased chemically induced liver and colon carcinogenesis, suggesting that PGC-1<italic>&#x003b1;</italic> may stimulate carcinogenesis [<xref rid="B80" ref-type="bibr">35</xref>]. Similarly, Shin et al. first demonstrated that overexpression of PGC-1<italic>&#x003b1;</italic> enhances cell proliferation and tumorigenesis via the upregulation of Sp1 and acyl-CoA binding protein [<xref rid="B81" ref-type="bibr">36</xref>]. It was also reported that PGC-1<italic>&#x003b1;</italic> overexpression leads to increased antioxidant enzymes (catalase, superoxide dismutase) and decreased ROS-induced apoptosis [<xref rid="B81" ref-type="bibr">36</xref>]. Similarly, PGC-1<italic>&#x003b1;</italic> knockdown significantly decreased cell number and induced apoptosis in PGC-1<italic>&#x003b1;</italic> positive melanoma cell lines, suggesting that PGC-1<italic>&#x003b1;</italic> is crucial in the survival of PGC-1<italic>&#x003b1;</italic> positive melanoma cells [<xref rid="B82" ref-type="bibr">37</xref>]. In addition, superoxide dismutase 2 protein levels were decreased in PGC-1<italic>&#x003b1;</italic> depleted melanoma cells. Moreover, ectopic expression of PGC-1<italic>&#x003b1;</italic> in melanoma cells increased the expression of ROS detoxifying genes. These data support the hypothesis that PGC-1<italic>&#x003b1;</italic> plays an important role in activating the ROS detoxification gene program to maintain melanoma cell survival [<xref rid="B82" ref-type="bibr">37</xref>]. Vazquez et al. also demonstrated that there was a significant reduction in tumor size in PGC-1<italic>&#x003b1;</italic> depleted cells, implying PGC-1<italic>&#x003b1;</italic> may be important in tumor progression [<xref rid="B82" ref-type="bibr">37</xref>]. De novo lipogenesis is a distinctive anabolic feature of malignant cells [<xref rid="B83" ref-type="bibr">94</xref>]. Carbons from glucose and glutamine supply cytoplasmic citrate for fatty acid synthesis with the help of lipogenic enzymes [<xref rid="B83" ref-type="bibr">94</xref>]. Glutamine can serve as an anaplerotic mitochondrial fuel and seems to be important for tumor survival [<xref rid="B84" ref-type="bibr">95</xref>]. In ErbB2-positive breast cancer cells, the PGC-1<italic>&#x003b1;</italic>/ERR<italic>&#x003b1;</italic> complex directly regulates the expression of glutamine metabolism enzymes, leading to the provision of glutamine carbons to de novo fatty acid synthesis [<xref rid="B85" ref-type="bibr">38</xref>]. PGC-1<italic>&#x003b1;</italic> overexpression, or ERR<italic>&#x003b1;</italic> activation, confers growth advantages of breast cancer cells even under limited nutrients, supporting the correlative clinical data that high expression of PGC-1<italic>&#x003b1;</italic> is associated with poor prognosis, possibly related to the activation of its downstream glutamine pathway target genes [<xref rid="B85" ref-type="bibr">38</xref>]. It was reported that PGC-1<italic>&#x003b1;</italic> expression is affected by various transcriptional pathways. One example is that melanocyte-lineage transcription master regulator and oncogene MITF activated PGC-1<italic>&#x003b1;</italic> expression in melanoma [<xref rid="B82" ref-type="bibr">37</xref>, <xref rid="B86" ref-type="bibr">91</xref>]. The decrease in mitochondrial membrane potential and increased ROS production with a decrease in glutathione, cystathionine, and 5-adenosylhomocysteine were observed in PGC-1<italic>&#x003b1;</italic>-depleted melanoma cell lines, suggesting that intrinsic apoptotic pathway is activated in PGC-1<italic>&#x003b1;</italic>-depleted melanoma cells [<xref rid="B82" ref-type="bibr">37</xref>]. Another example is that the androgen receptor-AMP-activated protein kinase (AMPK) signaling axis increased expression of PGC-1<italic>&#x003b1;</italic> to drive growth advantages in prostate cancers [<xref rid="B87" ref-type="bibr">39</xref>]. It was also shown that PGC-1<italic>&#x003b1;</italic> expression was significantly higher in lung adenocarcinomas with wild type p53 than in tumors with mutant p53 [<xref rid="B88" ref-type="bibr">40</xref>]. Cell proliferation was inhibited by PGC-1<italic>&#x003b1;</italic> siRNA knockdown experiments in H1944 lung adenocarcinoma cells [<xref rid="B88" ref-type="bibr">40</xref>]. In metabolic stress conditions, PGC-1<italic>&#x003b1;</italic> was shown, in complex with p53, to coactivate the transcription of cell cycle inhibitors, while it was also shown to promote the expression of genes related to mitochondrial biogenesis. These two functions are cooperative processes that promote cell survival. Moreover, oxidative stress in PGC-1<italic>&#x003b1;</italic> knockdown cells resulted in p53-induced apoptosis [<xref rid="B89" ref-type="bibr">96</xref>]. In turn, it was also shown that increased expression of PGC-1<italic>&#x003b1;</italic> might prevent p53-induced cell death by maintaining an adequate balance between oxidative phosphorylation and glycolysis [<xref rid="B90" ref-type="bibr">97</xref>].</p><p>Some studies have examined the effect of PGC-1<italic>&#x003b1;</italic> on angiogenesis. PGC-1<italic>&#x003b1;</italic> has been reported to activate the production of VEGF through the estrogen-related receptor <italic>&#x003b1;</italic>- (ERR<italic>&#x003b1;</italic>-) dependent pathway [<xref rid="B91" ref-type="bibr">98</xref>]. PGC-1<italic>&#x003b1;</italic> was shown to regulate HIF-1<italic>&#x003b1;</italic> activity. Increased PGC-1<italic>&#x003b1;</italic> expression enhances oxygen consumption, resulting in decreased local oxygen tension and increased HIF-1<italic>&#x003b1;</italic> stability [<xref rid="B92" ref-type="bibr">99</xref>]. In addition, HIF-2<italic>&#x003b1;</italic> is a transcriptional target of PGC-1<italic>&#x003b1;</italic>, even though the involved transcriptional mechanism is not clear [<xref rid="B93" ref-type="bibr">100</xref>]. ERR<italic>&#x003b1;</italic> is overexpressed in many cancers and its inhibition reduces cell proliferation. Recent studies suggest an important role for the interaction between PGC-1<italic>&#x003b1;</italic> and ERR<italic>&#x003b1;</italic> in cancer (reviewed in [<xref rid="B15" ref-type="bibr">15</xref>]). Kinase suppressor of ras 1 (KSR1), a molecular scaffold of the Raf/MEK/extracellular signal-regulated kinase (ERK) cascade, has been demonstrated to promote oncogenic Ras-dependent anchorage-independent growth through the activation of PGC-1<italic>&#x003b1;</italic> and ERR<italic>&#x003b1;</italic> [<xref rid="B94" ref-type="bibr">92</xref>]. Interestingly, recent study shows that PGC-1<italic>&#x003b1;</italic> plays an important role in the metastatic switch. LeBleu et al. demonstrated that circulating mammary epithelial cancer cells exhibit increased PGC-1<italic>&#x003b1;</italic> expression, enhanced mitochondrial biogenesis, and oxidative phosphorylation, which may contribute to distant metastasis and poor patient outcome [<xref rid="B95" ref-type="bibr">93</xref>]. In addition, PGC-1<italic>&#x003b1;</italic> knockdown decreased ATP production, reduced actin cytoskeleton remodeling, lowered anchorage-independent survival, and decreased intra-/extravasation, which are all checkpoints that prevent metastasis in MDA-MB-231 breast cancer and B16F10 melanoma cells [<xref rid="B95" ref-type="bibr">93</xref>]. LeBleu et al. also showed that PGC-1<italic>&#x003b1;</italic> expression in invasive cancer cells was significantly associated with the formation of distant metastases in a clinical analysis of human invasive breast cancers [<xref rid="B95" ref-type="bibr">93</xref>].</p></sec><sec id="sec3.2"><title>3.2. Anticancer Functions of PGC-1<italic>&#x003b1;</italic></title><p>As opposed to the tumor-promoting role of PGC-1<italic>&#x003b1;</italic> described above, several studies have shown that PGC-1<italic>&#x003b1;</italic> has anticancer effects. As described above, PGC-1<italic>&#x003b1;</italic> is decreased in colon [<xref rid="B75" ref-type="bibr">88</xref>], breast [<xref rid="B76" ref-type="bibr">89</xref>], and ovarian cancer cells [<xref rid="B77" ref-type="bibr">41</xref>], and PGC-1<italic>&#x003b1;</italic> overexpression in human ovarian cancer cell line Ho-8910 has been shown to induce apoptosis via downregulation of Bcl-1 and upregulation of Bax, suggesting that PGC-1<italic>&#x003b1;</italic> may be a contributor to the inhibition of tumor growth [<xref rid="B77" ref-type="bibr">41</xref>]. Lee et al. found that PPAR<italic>&#x003b3;</italic> activation and PGC-1<italic>&#x003b1;</italic> overexpression by adenovirus infection in HepG2 human hepatoma cells induced E-cadherin upregulation and inhibited cell motility [<xref rid="B96" ref-type="bibr">42</xref>]. One report showed that PGC-1<italic>&#x003b1;</italic> overexpression induced apoptosis via ROS accumulation in HT29 and HCT116 colorectal cancer cells. In addition, PGC-1<italic>&#x003b1;</italic> overexpression reduced tumor growth in an HT29 xenograft model, suggesting a role of PGC-1<italic>&#x003b1;</italic> as a tumor suppressor [<xref rid="B97" ref-type="bibr">43</xref>]. Zhang et al. reported that von Hippel-Lindau- (VHL-) deficient clear cell renal carcinomas exhibited higher levels of HIF-1<italic>&#x003b1;</italic> and enhanced glycolysis [<xref rid="B98" ref-type="bibr">101</xref>]. HIF-1<italic>&#x003b1;</italic> is known to induce the expression of transcriptional repressor Dec1, which leads to the suppression of PGC-1<italic>&#x003b1;</italic> expression and the inhibition of mitochondrial respiration [<xref rid="B99" ref-type="bibr">102</xref>]. However, the enforced PGC-1<italic>&#x003b1;</italic> expression in VHL-deficient cells, despite the restoration of mitochondrial function, did not block the inhibition of cell growth and enhanced sensitivity to cytotoxic therapies in oxidative stress conditions [<xref rid="B99" ref-type="bibr">102</xref>]. This is in line with clinical clear cell carcinoma data that showed the correlation of higher mitochondrial mass with reduced tumor aggressiveness [<xref rid="B100" ref-type="bibr">103</xref>], and the association of lower PGC-1<italic>&#x003b1;</italic> levels with worse patient outcome [<xref rid="B99" ref-type="bibr">102</xref>]. It was shown that PGC-1<italic>&#x003b1;</italic> attenuates stress responses necessary for cancer cell survival, by interacting with heat-shock factor 1 [<xref rid="B101" ref-type="bibr">104</xref>]. Wang and Moraes revealed that increased PGC-1<italic>&#x003b1;</italic> expression due to treatment with PPAR panagonist (bezafibrate) increased mitochondrial biogenesis, resulting in an inhibition of cancer cell proliferation under glycolytic conditions and inhibition of invasion [<xref rid="B102" ref-type="bibr">44</xref>]. In addition, PGC-1<italic>&#x003b1;</italic> downregulation by miRNA-217 led to the promotion of cancer cell proliferation in breast cancer cells, suggesting a role of PGC-1<italic>&#x003b1;</italic> as a tumor suppressor [<xref rid="B103" ref-type="bibr">105</xref>]. Recently, Torrano et al. showed that PGC-1<italic>&#x003b1;</italic> suppresses metastasis of prostate carcinoma through an ERR<italic>&#x003b1;</italic>-dependent transcriptional program [<xref rid="B104" ref-type="bibr">45</xref>]. Highly metastatic melanoma cells expressed lower levels of PGC-1<italic>&#x003b1;</italic> [<xref rid="B106" ref-type="bibr">46</xref>, <xref rid="B105" ref-type="bibr">106</xref>]. In turn, these PGC-1<italic>&#x003b1;</italic>-low cells expressed higher levels of integrin, TGF<italic>&#x003b2;</italic>, and Wnt signaling components involved in metastasis. It was shown that genetic depletion of PGC-1<italic>&#x003b1;</italic> increased metastasis in poorly invasive melanoma cells [<xref rid="B106" ref-type="bibr">46</xref>]. In contrast, PGC-1<italic>&#x003b1;</italic> overexpression in melanoma cells by ectopic expression or exposure to BRAF<sup>V600E</sup> inhibitor vemurafenib suppressed metastasis through the direct regulation of inhibitor of DNA binding protein 2 (ID2) and inhibition of TCF-mediated gene transcription [<xref rid="B106" ref-type="bibr">46</xref>].</p><p>As described above, there have been many studies of the role of PGC-1<italic>&#x003b1;</italic> in tumor progression. However, it is still not sure if PGC-1<italic>&#x003b1;</italic> acts as a tumor promoter or tumor suppressor, and to date it is thought that its effect on tumor varies depending on the tissue context and tumor type (reviewed in [<xref rid="B107" ref-type="bibr">107</xref>]).</p></sec></sec><sec id="sec4"><title>4. Conclusions</title><p>PPAR<italic>&#x003b3;</italic> and PGC-1<italic>&#x003b1;</italic> are emerging proteins involved in tumorigenesis and attractive topics to study for further understanding of cancer biology. Originally, PGC-1<italic>&#x003b1;</italic> was identified as a PPAR<italic>&#x003b3;</italic> interacting protein. However, most of the reported actions of PGC-1<italic>&#x003b1;</italic> in cancer were not related to the expression of PPAR<italic>&#x003b3;</italic>. Despite the fact that PPAR<italic>&#x003b3;</italic> and PGC-1<italic>&#x003b1;</italic> can each act as both tumor promoter and tumor suppressor, there is no clearly defined mechanism that can explain the contradictory dual effects. However, their dual actions can be explained, in part, by their cell type-specific effects and variable interacting proteins. Therefore, each of the molecular interactions of PPAR<italic>&#x003b3;</italic> and PGC-1<italic>&#x003b1;</italic> with other transcriptional partners needs to be further investigated to understand the role of PPAR<italic>&#x003b3;</italic> and PGC-1<italic>&#x003b1;</italic> in cancer.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT &#x00026; Future Planning (2017R1A2B4011428).</p></ack><sec><title>Conflicts of Interest</title><p>The authors declare that they have no conflicts of interest.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangelsdorf</surname><given-names>D. J.</given-names></name><name><surname>Thummel</surname><given-names>C.</given-names></name><name><surname>Beato</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The nuclear receptor super-family: the second decade</article-title><source><italic>Cell</italic></source><year>1995</year><volume>83</volume><issue>6</issue><fpage>835</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90199-X</pub-id><pub-id pub-id-type="other">2-s2.0-0012473279</pub-id><pub-id pub-id-type="pmid">8521507</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoonjans</surname><given-names>K.</given-names></name><name><surname>Staels</surname><given-names>B.</given-names></name><name><surname>Auwerx</surname><given-names>J.</given-names></name></person-group><article-title>The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation</article-title><source><italic>Biochimica et Biophysica Acta&#x02014;Lipids and Lipid Metabolism</italic></source><year>1996</year><volume>1302</volume><issue>2</issue><fpage>93</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/0005-2760(96)00066-5</pub-id><pub-id pub-id-type="other">2-s2.0-0030602866</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willson</surname><given-names>T. M.</given-names></name><name><surname>Brown</surname><given-names>P. J.</given-names></name><name><surname>Sternbach</surname><given-names>D. D.</given-names></name><name><surname>Henke</surname><given-names>B. R.</given-names></name></person-group><article-title>The PPARs: from orphan receptors to drug discovery</article-title><source><italic>Journal of Medicinal Chemistry</italic></source><year>2000</year><volume>43</volume><issue>4</issue><fpage>527</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1021/jm990554g</pub-id><pub-id pub-id-type="other">2-s2.0-0033998334</pub-id><pub-id pub-id-type="pmid">10691680</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tontonoz</surname><given-names>P.</given-names></name><name><surname>Hu</surname><given-names>E.</given-names></name><name><surname>Graves</surname><given-names>R. A.</given-names></name><name><surname>Budavari</surname><given-names>A. I.</given-names></name><name><surname>Spiegelman</surname><given-names>B. M.</given-names></name></person-group><article-title>mPPAR<italic>&#x003b3;</italic>2: tissue-specific regulator of an adipocyte enhancer</article-title><source><italic>Genes &#x00026; Development</italic></source><year>1994</year><volume>8</volume><issue>10</issue><fpage>1224</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.1101/gad.8.10.1224</pub-id><pub-id pub-id-type="other">2-s2.0-0028180070</pub-id><pub-id pub-id-type="pmid">7926726</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fajas</surname><given-names>L.</given-names></name><name><surname>Auboeuf</surname><given-names>D.</given-names></name><name><surname>Rasp&#x000e9;</surname><given-names>E.</given-names></name><etal/></person-group><article-title>The organization, promoter analysis, and expression of the human PPAR<italic>&#x003b3;</italic> gene</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>1997</year><volume>272</volume><issue>30</issue><fpage>18779</fpage><lpage>18789</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.30.18779</pub-id><pub-id pub-id-type="other">2-s2.0-0030835678</pub-id><pub-id pub-id-type="pmid">9228052</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tontonoz</surname><given-names>P.</given-names></name><name><surname>Hu</surname><given-names>E.</given-names></name><name><surname>Spiegelman</surname><given-names>B. M.</given-names></name></person-group><article-title>Stimulation of adipogenesis in fibroblasts by PPAR<italic>&#x003b3;</italic>2, a lipid-activated transcription factor</article-title><source><italic>Cell</italic></source><year>1994</year><volume>79</volume><issue>7</issue><fpage>1147</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(94)90006-X</pub-id><pub-id pub-id-type="other">2-s2.0-0028641559</pub-id><pub-id pub-id-type="pmid">8001151</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J. I.</given-names></name></person-group><article-title>The role of 15d-PGJ<sub>2</sub>, a natural ligand for peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> (PPAR<italic>&#x003b3;</italic>), in cancer</article-title><source><italic>Cellular and Genetic Practices for Translational Medicine</italic></source><year>2011</year><fpage>169</fpage><lpage>195</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.-I.</given-names></name><name><surname>Kwak</surname><given-names>J.-Y.</given-names></name></person-group><article-title>The role of peroxisome proliferator-activated receptors in colorectal cancer</article-title><source><italic>PPAR Research</italic></source><year>2012</year><volume>2012</volume><fpage>12</fpage><pub-id pub-id-type="publisher-id">876418</pub-id><pub-id pub-id-type="doi">10.1155/2012/876418</pub-id><pub-id pub-id-type="other">2-s2.0-84867379854</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puigserver</surname><given-names>P.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Park</surname><given-names>C. W.</given-names></name><name><surname>Graves</surname><given-names>R.</given-names></name><name><surname>Wright</surname><given-names>M.</given-names></name><name><surname>Spiegelman</surname><given-names>B. M.</given-names></name></person-group><article-title>A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis</article-title><source><italic>Cell</italic></source><year>1998</year><volume>92</volume><issue>6</issue><fpage>829</fpage><lpage>839</lpage><pub-id pub-id-type="other">2-s2.0-0032549811</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81410-5</pub-id><pub-id pub-id-type="pmid">9529258</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Tarr</surname><given-names>P. T.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><etal/></person-group><article-title>PGC-1<italic>&#x003b2;</italic> in the regulation of hepatic glucose and energy metabolism</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2003</year><volume>278</volume><issue>33</issue><fpage>30843</fpage><lpage>30848</lpage><pub-id pub-id-type="doi">10.1074/jbc.m303643200</pub-id><pub-id pub-id-type="other">2-s2.0-0042232315</pub-id><pub-id pub-id-type="pmid">12807885</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kressler</surname><given-names>D.</given-names></name><name><surname>Schreiber</surname><given-names>S. N.</given-names></name><name><surname>Knutti</surname><given-names>D.</given-names></name><name><surname>Kralli</surname><given-names>A.</given-names></name></person-group><article-title>The PGC-1-related protein PERC is a selective coactivator of estrogen receptor <italic>&#x003b1;</italic></article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2002</year><volume>277</volume><issue>16</issue><fpage>13918</fpage><lpage>13925</lpage><pub-id pub-id-type="other">2-s2.0-0037134493</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M201134200</pub-id><pub-id pub-id-type="pmid">11854298</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>U.</given-names></name><name><surname>Scarpulla</surname><given-names>R. C.</given-names></name></person-group><article-title>PGC-1-related coactivator, a novel, serum-inducible coactivator of nuclear respiratory factor 1-dependent transcription in mammalian cells</article-title><source><italic>Molecular and Cellular Biology</italic></source><year>2001</year><volume>21</volume><issue>11</issue><fpage>3738</fpage><lpage>3749</lpage><pub-id pub-id-type="doi">10.1128/mcb.21.11.3738-3749.2001</pub-id><pub-id pub-id-type="other">2-s2.0-0035016566</pub-id><pub-id pub-id-type="pmid">11340167</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Puigserver</surname><given-names>P.</given-names></name><name><surname>Donovan</surname><given-names>J.</given-names></name><name><surname>Tarr</surname><given-names>P.</given-names></name><name><surname>Spiegelman</surname><given-names>B. M.</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> coactivator 1<italic>&#x003b2;</italic> (PGC-1<italic>&#x003b2;</italic>), a novel PGC-1-related transcription coactivator associated with host cell factor</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2002</year><volume>277</volume><issue>3</issue><fpage>1645</fpage><lpage>1648</lpage><pub-id pub-id-type="doi">10.1074/jbc.c100631200</pub-id><pub-id pub-id-type="other">2-s2.0-0037127204</pub-id><pub-id pub-id-type="pmid">11733490</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monsalve</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Adelmant</surname><given-names>G.</given-names></name><name><surname>Puigserver</surname><given-names>P.</given-names></name><name><surname>Fan</surname><given-names>M.</given-names></name><name><surname>Spiegelman</surname><given-names>B. M.</given-names></name></person-group><article-title>Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1</article-title><source><italic>Molecular Cell</italic></source><year>2000</year><volume>6</volume><issue>2</issue><fpage>307</fpage><lpage>316</lpage><pub-id pub-id-type="other">2-s2.0-0033638283</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(00)00031-9</pub-id><pub-id pub-id-type="pmid">10983978</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girnun</surname><given-names>G. D.</given-names></name></person-group><article-title>The diverse role of the PPAR<italic>&#x003b3;</italic> coactivator 1 family of transcriptional coactivators in cancer</article-title><source><italic>Seminars in Cell &#x00026; Developmental Biology</italic></source><year>2012</year><volume>23</volume><issue>4</issue><fpage>381</fpage><lpage>388</lpage><pub-id pub-id-type="other">2-s2.0-84861980898</pub-id><pub-id pub-id-type="doi">10.1016/j.semcdb.2012.01.007</pub-id><pub-id pub-id-type="pmid">22285815</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Xin</surname><given-names>Y.</given-names></name></person-group><article-title>Down-regulated expressions of PPAR<italic>&#x003b3;</italic> and its coactivator PGC-1 are related to gastric carcinogenesis and Lauren&#x02019;s classification in gastric carcinoma</article-title><source><italic>Chinese Journal of Cancer Research</italic></source><year>2013</year><volume>25</volume><issue>6</issue><fpage>704</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">24385698</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiota</surname><given-names>M.</given-names></name><name><surname>Yokomizo</surname><given-names>A.</given-names></name><name><surname>Tada</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> coactivator-1<italic>&#x003b1;</italic> interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR</article-title><source><italic>Molecular Endocrinology</italic></source><year>2010</year><volume>24</volume><issue>1</issue><fpage>114</fpage><lpage>127</lpage><pub-id pub-id-type="other">2-s2.0-73549114238</pub-id><pub-id pub-id-type="doi">10.1210/me.2009-0302</pub-id><pub-id pub-id-type="pmid">19884383</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansure</surname><given-names>J. J.</given-names></name><name><surname>Nassim</surname><given-names>R.</given-names></name><name><surname>Kassouf</surname><given-names>W.</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> in bladder cancer: A promising therapeutic target</article-title><source><italic>Cancer Biology &#x00026; Therapy</italic></source><year>2009</year><volume>8</volume><issue>7</issue><fpage>6</fpage><lpage>15</lpage><pub-id pub-id-type="other">2-s2.0-66149157824</pub-id><pub-id pub-id-type="pmid">19417560</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DuBois</surname><given-names>R. N.</given-names></name><name><surname>Gupta</surname><given-names>R.</given-names></name><name><surname>Brockman</surname><given-names>J.</given-names></name><name><surname>Reddy</surname><given-names>B. S.</given-names></name><name><surname>Krakow</surname><given-names>S. L.</given-names></name><name><surname>Lazar</surname><given-names>M. A.</given-names></name></person-group><article-title>The nuclear eicosanoid receptor, PPAR<italic>&#x003b3;</italic>, is aberrantly expressed in colonic cancers</article-title><source><italic>Carcinogenesis</italic></source><year>1998</year><volume>19</volume><issue>1</issue><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1093/carcin/19.1.49</pub-id><pub-id pub-id-type="other">2-s2.0-0031844535</pub-id><pub-id pub-id-type="pmid">9472692</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarraf</surname><given-names>P.</given-names></name><name><surname>Mueller</surname><given-names>E.</given-names></name><name><surname>Jones</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Differentiation and reversal of malignant changes in colon cancer through PPAR<italic>&#x003b3;</italic></article-title><source><italic>Nature Medicine</italic></source><year>1998</year><volume>4</volume><issue>9</issue><fpage>1046</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1038/2030</pub-id><pub-id pub-id-type="other">2-s2.0-0031671246</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>E.</given-names></name><name><surname>Sarraf</surname><given-names>P.</given-names></name><name><surname>Tontonoz</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Terminal differentiation of human breast cancer through PPAR<italic>&#x003b3;</italic></article-title><source><italic>Molecular Cell</italic></source><year>1998</year><volume>1</volume><issue>3</issue><fpage>465</fpage><lpage>470</lpage><pub-id pub-id-type="other">2-s2.0-0031993322</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(00)80047-7</pub-id><pub-id pub-id-type="pmid">9660931</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubota</surname><given-names>T.</given-names></name><name><surname>Koshizuka</surname><given-names>K.</given-names></name><name><surname>Williamson</surname><given-names>E. A.</given-names></name><etal/></person-group><article-title>Ligand for peroxisome proliferator-activated receptor gamma (Troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo</article-title><source><italic>Cancer Research</italic></source><year>1998</year><volume>58</volume><issue>15</issue><fpage>3344</fpage><lpage>3352</lpage><pub-id pub-id-type="other">2-s2.0-0032145363</pub-id><pub-id pub-id-type="pmid">9699665</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Han</surname><given-names>Z. C.</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> in malignant diseases</article-title><source><italic>Critical Reviews in Oncology/Hematology</italic></source><year>2006</year><volume>58</volume><issue>1</issue><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2005.08.011</pub-id><pub-id pub-id-type="other">2-s2.0-33644954823</pub-id><pub-id pub-id-type="pmid">16388966</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ban</surname><given-names>J. O.</given-names></name><name><surname>Kwak</surname><given-names>D. H.</given-names></name><name><surname>Oh</surname><given-names>J. H.</given-names></name><etal/></person-group><article-title>Suppression of NF-<italic>&#x003ba;</italic>B and GSK-3<italic>&#x003b2;</italic> is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone</article-title><source><italic>Chemico-Biological Interactions</italic></source><year>2010</year><volume>188</volume><issue>1</issue><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2010.06.001</pub-id><pub-id pub-id-type="other">2-s2.0-77956172120</pub-id><pub-id pub-id-type="pmid">20540935</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N. J.</given-names></name><name><surname>Oh</surname><given-names>J. H.</given-names></name><name><surname>Ban</surname><given-names>J. O.</given-names></name><etal/></person-group><article-title>4-O-methylhonokiol, a PPAR<italic>&#x003b3;</italic> agonist, inhibits prostate tumour growth: P21-mediated suppression of NF-kB activity</article-title><source><italic>British Journal of Pharmacology</italic></source><year>2013</year><volume>168</volume><issue>5</issue><fpage>1133</fpage><lpage>1145</lpage><pub-id pub-id-type="other">2-s2.0-84874275656</pub-id><pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.02235.x</pub-id><pub-id pub-id-type="pmid">23043610</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>Y.</given-names></name><name><surname>Moreau</surname><given-names>F.</given-names></name><name><surname>Chadee</surname><given-names>K.</given-names></name></person-group><article-title>PPAR<italic>&#x003b3;</italic> is an E3 ligase that induces the degradation of NF<italic>&#x003ba;</italic>B/p65</article-title><source><italic>Nature Communications</italic></source><year>2012</year><volume>3, article 1300</volume><pub-id pub-id-type="doi">10.1038/ncomms2270</pub-id><pub-id pub-id-type="other">2-s2.0-84871766892</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>PPAR<italic>&#x003b3;</italic> E3 ubiquitin ligase regulates MUC1-C oncoprotein stability</article-title><source><italic>Oncogene</italic></source><year>2014</year><volume>33</volume><issue>49</issue><fpage>5619</fpage><lpage>5625</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.504</pub-id><pub-id pub-id-type="other">2-s2.0-84888346453</pub-id><pub-id pub-id-type="pmid">24292674</pub-id></element-citation></ref><ref id="B34"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawayama</surname><given-names>H.</given-names></name><name><surname>Ishimoto</surname><given-names>T.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Small molecule agonists of PPAR-<italic>&#x003b3;</italic> exert therapeutic effects in esophageal cancer</article-title><source><italic>Cancer Research</italic></source><year>2014</year><volume>74</volume><issue>2</issue><fpage>575</fpage><lpage>585</lpage><pub-id pub-id-type="other">2-s2.0-84892935469</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1836</pub-id><pub-id pub-id-type="pmid">24272485</pub-id></element-citation></ref><ref id="B37"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papi</surname><given-names>A.</given-names></name><name><surname>De Carolis</surname><given-names>S.</given-names></name><name><surname>Bertoni</surname><given-names>S.</given-names></name><etal/></person-group><article-title>PPARgamma and RXR ligands disrupt the inflammatory cross-talk in the hypoxic breast cancer stem cells niche</article-title><source><italic>Journal of Cellular Physiology</italic></source><year>2014</year><volume>229</volume><issue>11</issue><fpage>1595</fpage><lpage>1606</lpage><pub-id pub-id-type="doi">10.1002/jcp.24601</pub-id><pub-id pub-id-type="other">2-s2.0-84904876378</pub-id><pub-id pub-id-type="pmid">24604522</pub-id></element-citation></ref><ref id="B38"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prost</surname><given-names>S.</given-names></name><name><surname>Relouzat</surname><given-names>F.</given-names></name><name><surname>Spentchian</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Erosion of the chronic myeloid leukaemia stem cell pool by PPAR<italic>&#x003b3;</italic> agonists</article-title><source><italic>Nature</italic></source><year>2015</year><volume>525</volume><issue>7569</issue><fpage>380</fpage><lpage>383</lpage><pub-id pub-id-type="other">2-s2.0-84942036511</pub-id><pub-id pub-id-type="doi">10.1038/nature15248</pub-id><?supplied-pmid 26331539?><pub-id pub-id-type="pmid">26331539</pub-id></element-citation></ref><ref id="B42"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Ren</surname><given-names>X.</given-names></name><name><surname>Dong</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Constitutive expression of PPAR<italic>&#x003b3;</italic> inhibits proliferation and migration of gastric cancer cells and down-regulates Wnt/<italic>&#x003b2;</italic>-catenin signaling pathway downstream target genes TERT and ENAH</article-title><source><italic>Gene</italic></source><year>2016</year><volume>584</volume><issue>1</issue><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2016.03.003</pub-id><pub-id pub-id-type="pmid">26956036</pub-id></element-citation></ref><ref id="B48"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pseftogas</surname><given-names>A.</given-names></name><name><surname>Gonidas</surname><given-names>C.</given-names></name><name><surname>Mosialos</surname><given-names>G.</given-names></name></person-group><article-title>Activation of peroxisome proliferator-activated receptor gamma in mammary epithelial cells upregulates the expression of tumor suppressor Cyld to mediate growth inhibition and anti-inflammatory effects</article-title><source><italic>The International Journal of Biochemistry &#x00026; Cell Biology</italic></source><year>2017</year><volume>82</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="other">2-s2.0-85002748673</pub-id><pub-id pub-id-type="doi">10.1016/j.biocel.2016.11.011</pub-id><pub-id pub-id-type="pmid">27865894</pub-id></element-citation></ref><ref id="B52"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rovito</surname><given-names>D.</given-names></name><name><surname>Gionfriddo</surname><given-names>G.</given-names></name><name><surname>Barone</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Ligand-activated PPAR<italic>&#x003b3;</italic> downregulates CXCR4 gene expression through a novel identified PPAR response element and inhibits breast cancer progression</article-title><source><italic>Oncotarget</italic></source><year>2016</year><volume>7</volume><issue>40</issue><fpage>65109</fpage><lpage>65124</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.11371</pub-id><pub-id pub-id-type="pmid">27556298</pub-id></element-citation></ref><ref id="B79"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Hong</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Aberrant cell proliferation by enhanced mitochondrial biogenesis via mtTFA in arsenical skin cancers</article-title><source><italic>The American Journal of Pathology</italic></source><year>2011</year><volume>178</volume><issue>5</issue><fpage>2066</fpage><lpage>2076</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2011.01.056</pub-id><pub-id pub-id-type="other">2-s2.0-79959245405</pub-id><pub-id pub-id-type="pmid">21514422</pub-id></element-citation></ref><ref id="B80"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhalla</surname><given-names>K.</given-names></name><name><surname>Hwang</surname><given-names>B. J.</given-names></name><name><surname>Dewi</surname><given-names>R. E.</given-names></name><etal/></person-group><article-title>PGC1<italic>&#x003b1;</italic> promotes tumor growth by inducing gene expression programs supporting lipogenesis</article-title><source><italic>Cancer Research</italic></source><year>2011</year><volume>71</volume><issue>21</issue><fpage>6888</fpage><lpage>6898</lpage><pub-id pub-id-type="other">2-s2.0-80155126156</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1011</pub-id><pub-id pub-id-type="pmid">21914785</pub-id></element-citation></ref><ref id="B81"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>S.-W.</given-names></name><name><surname>Yun</surname><given-names>S.-H.</given-names></name><name><surname>Park</surname><given-names>E.-S.</given-names></name><name><surname>Jeong</surname><given-names>J.-S.</given-names></name><name><surname>Kwak</surname><given-names>J.-Y.</given-names></name><name><surname>Park</surname><given-names>J.-I.</given-names></name></person-group><article-title>Overexpression of PGC-1<italic>&#x003b1;</italic> enhances cell proliferation and tumorigenesis of HEK293 cells through the upregulation of Sp1 and Acyl-CoA binding protein</article-title><source><italic>International Journal of Oncology</italic></source><year>2015</year><volume>46</volume><issue>3</issue><fpage>1328</fpage><lpage>1342</lpage><pub-id pub-id-type="other">2-s2.0-84921919048</pub-id><pub-id pub-id-type="doi">10.3892/ijo.2015.2834</pub-id><pub-id pub-id-type="pmid">25585584</pub-id></element-citation></ref><ref id="B82"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vazquez</surname><given-names>F.</given-names></name><name><surname>Lim</surname><given-names>J.-H.</given-names></name><name><surname>Chim</surname><given-names>H.</given-names></name><etal/></person-group><article-title>PGC1<italic>&#x003b1;</italic> expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress</article-title><source><italic>Cancer Cell</italic></source><year>2013</year><volume>23</volume><issue>3</issue><fpage>287</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.11.020</pub-id><pub-id pub-id-type="other">2-s2.0-84876448550</pub-id><pub-id pub-id-type="pmid">23416000</pub-id></element-citation></ref><ref id="B85"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuirk</surname><given-names>S.</given-names></name><name><surname>Gravel</surname><given-names>S.</given-names></name><name><surname>Deblois</surname><given-names>G.</given-names></name><etal/></person-group><article-title>PGC-1<italic>&#x003b1;</italic> supports glutamine metabolism in breast cancer</article-title><source><italic>Cancer &#x00026; Metabolism</italic></source><year>2013</year><volume>5</volume><issue>1</issue><fpage>p. 22</fpage><pub-id pub-id-type="doi">10.1186/2049-3002-1-22</pub-id></element-citation></ref><ref id="B87"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tennakoon</surname><given-names>J. B.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>J. J.</given-names></name><etal/></person-group><article-title>Androgens regulate prostate cancer cell growth via an AMPK-PGC-1<italic>&#x003b1;</italic>-mediated metabolic switch</article-title><source><italic>Oncogene</italic></source><year>2014</year><volume>33</volume><issue>45</issue><fpage>5251</fpage><lpage>5261</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.463</pub-id><pub-id pub-id-type="other">2-s2.0-84924860869</pub-id><pub-id pub-id-type="pmid">24186207</pub-id></element-citation></ref><ref id="B88"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taguchi</surname><given-names>A.</given-names></name><name><surname>Delgado</surname><given-names>O.</given-names></name><name><surname>&#x000c7;elikta&#x0015f;</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Proteomic signatures associated with p53 mutational status in lung adenocarcinoma</article-title><source><italic>Proteomics</italic></source><year>2014</year><volume>14</volume><issue>23-24</issue><fpage>2750</fpage><lpage>2759</lpage><pub-id pub-id-type="other">2-s2.0-84913573550</pub-id><pub-id pub-id-type="doi">10.1002/pmic.201400378</pub-id><pub-id pub-id-type="pmid">25331784</pub-id></element-citation></ref><ref id="B77"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Ba</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>PGC-1<italic>&#x003b1;</italic> induces apoptosis in human epithelial ovarian cancer cells through a PPAR<italic>&#x003b3;</italic>-dependent pathway</article-title><source><italic>Cell Research</italic></source><year>2007</year><volume>17</volume><issue>4</issue><fpage>363</fpage><lpage>373</lpage><pub-id pub-id-type="other">2-s2.0-34247346466</pub-id><pub-id pub-id-type="doi">10.1038/cr.2007.11</pub-id><pub-id pub-id-type="pmid">17372612</pub-id></element-citation></ref><ref id="B96"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H. J.</given-names></name><name><surname>Su</surname><given-names>Y.</given-names></name><name><surname>Yin</surname><given-names>P. H.</given-names></name><name><surname>Lee</surname><given-names>H. C.</given-names></name><name><surname>Chi</surname><given-names>C. W.</given-names></name></person-group><article-title>PPAR<italic>&#x003b3;</italic>/PGC-1<italic>&#x003b1;</italic> pathway in E-cadherin expression and motility of HepG2 cells</article-title><source><italic>Anticancer Research</italic></source><year>2009</year><volume>29</volume><issue>12</issue><fpage>5057</fpage><lpage>5063</lpage><pub-id pub-id-type="pmid">20044617</pub-id></element-citation></ref><ref id="B97"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Errico</surname><given-names>I.</given-names></name><name><surname>Salvatore</surname><given-names>L.</given-names></name><name><surname>Murzilli</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> coactivator 1-<italic>&#x003b1;</italic> (PGC1<italic>&#x003b1;</italic>) is a metabolic regulator of intestinal epithelial cell fate</article-title><source><italic>Proceedings of the National Acadamy of Sciences of the United States of America</italic></source><year>2011</year><volume>108</volume><issue>16</issue><fpage>6603</fpage><lpage>6608</lpage><pub-id pub-id-type="other">2-s2.0-79955634801</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1016354108</pub-id></element-citation></ref><ref id="B102"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Moraes</surname><given-names>C. T.</given-names></name></person-group><article-title>Increases in mitochondrial biogenesis impair carcinogenesis at multiple levels</article-title><source><italic>Molecular Oncology</italic></source><year>2011</year><volume>5</volume><issue>5</issue><fpage>399</fpage><lpage>409</lpage><pub-id pub-id-type="other">2-s2.0-80053132439</pub-id><pub-id pub-id-type="doi">10.1016/j.molonc.2011.07.008</pub-id><pub-id pub-id-type="pmid">21855427</pub-id></element-citation></ref><ref id="B104"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torrano</surname><given-names>V.</given-names></name><name><surname>Valcarcel-Jimenez</surname><given-names>L.</given-names></name><name><surname>Cortazar</surname><given-names>A. R.</given-names></name><etal/></person-group><article-title>The metabolic co-regulator PGC1<italic>&#x003b1;</italic> suppresses prostate cancer metastasis</article-title><source><italic>Nature Cell Biology</italic></source><year>2016</year><volume>18</volume><issue>6</issue><fpage>645</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1038/ncb3357</pub-id><pub-id pub-id-type="other">2-s2.0-84969816000</pub-id><pub-id pub-id-type="pmid">27214280</pub-id></element-citation></ref><ref id="B106"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>C.</given-names></name><name><surname>Lim</surname><given-names>J.-H.</given-names></name><name><surname>Lee</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A PGC1<italic>&#x003b1;</italic>-mediated transcriptional axis suppresses melanoma metastasis</article-title><source><italic>Nature</italic></source><year>2016</year><volume>537</volume><issue>7620</issue><fpage>422</fpage><lpage>426</lpage><pub-id pub-id-type="other">2-s2.0-84988432420</pub-id><pub-id pub-id-type="doi">10.1038/nature19347</pub-id><pub-id pub-id-type="pmid">27580028</pub-id></element-citation></ref><ref id="B28"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>R.</given-names></name><name><surname>Raina</surname><given-names>D.</given-names></name><name><surname>Trivedi</surname><given-names>V.</given-names></name><etal/></person-group><article-title>MUC1 oncoprotein activates the I<italic>&#x003ba;</italic>B kinase <italic>&#x003b2;</italic> complex and constitutive NF-<italic>&#x003ba;</italic>B signalling</article-title><source><italic>Nature Cell Biology</italic></source><year>2007</year><volume>9</volume><issue>12</issue><fpage>1419</fpage><lpage>1427</lpage><pub-id pub-id-type="other">2-s2.0-36749092728</pub-id><pub-id pub-id-type="doi">10.1038/ncb1661</pub-id><pub-id pub-id-type="pmid">18037881</pub-id></element-citation></ref><ref id="B29"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascio</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Finn</surname><given-names>O. J.</given-names></name></person-group><article-title>MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-<italic>&#x003ba;</italic>B p65 and binding to cytokine promoters: Importance of extracellular domain</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2011</year><volume>286</volume><issue>49</issue><fpage>42248</fpage><lpage>42256</lpage><pub-id pub-id-type="other">2-s2.0-82755195700</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M111.297630</pub-id><pub-id pub-id-type="pmid">22021035</pub-id></element-citation></ref><ref id="B30"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>R.</given-names></name><name><surname>Raina</surname><given-names>D.</given-names></name><name><surname>Joshi</surname><given-names>M. D.</given-names></name><etal/></person-group><article-title>MUC1-C oncoprotein functions as a direct activator of the nuclear factor-<italic>&#x003ba;</italic>B p65 transcription factor</article-title><source><italic>Cancer Research</italic></source><year>2009</year><volume>69</volume><issue>17</issue><fpage>7013</fpage><lpage>7021</lpage><pub-id pub-id-type="other">2-s2.0-70149111064</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-0523</pub-id><pub-id pub-id-type="pmid">19706766</pub-id></element-citation></ref><ref id="B31"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>R.</given-names></name><name><surname>Rajabi</surname><given-names>H.</given-names></name><name><surname>Kosugi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop</article-title><source><italic>Science Signaling</italic></source><year>2011</year><volume>4</volume><issue>160, article no. ra9</issue><pub-id pub-id-type="other">2-s2.0-79951904086</pub-id><pub-id pub-id-type="doi">10.1126/scisignal.2001426</pub-id></element-citation></ref><ref id="B32"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Kufe</surname><given-names>D.</given-names></name></person-group><article-title>Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response</article-title><source><italic>Cancer Cell</italic></source><year>2005</year><volume>7</volume><issue>2</issue><fpage>167</fpage><lpage>178</lpage><pub-id pub-id-type="other">2-s2.0-13844262819</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2005.01.008</pub-id><pub-id pub-id-type="pmid">15710329</pub-id></element-citation></ref><ref id="B33"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>R.</given-names></name><name><surname>Alam</surname><given-names>M.</given-names></name><name><surname>Rajabi</surname><given-names>H.</given-names></name><name><surname>Kufe</surname><given-names>D.</given-names></name></person-group><article-title>The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2012</year><volume>287</volume><issue>25</issue><fpage>20866</fpage><lpage>20875</lpage><pub-id pub-id-type="other">2-s2.0-84862304215</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M112.357293</pub-id><pub-id pub-id-type="pmid">22544745</pub-id></element-citation></ref><ref id="B35"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apsel Winger</surname><given-names>B.</given-names></name><name><surname>Shah</surname><given-names>N. P.</given-names></name></person-group><article-title>PPAR<italic>&#x003b3;</italic>: Welcoming the New Kid on the CML Stem Cell Block</article-title><source><italic>Cancer Cell</italic></source><year>2015</year><volume>28</volume><issue>4, article no. 2152</issue><fpage>409</fpage><lpage>411</lpage><pub-id pub-id-type="other">2-s2.0-84944076734</pub-id><pub-id pub-id-type="doi">10.1016/j.ccell.2015.09.017</pub-id><pub-id pub-id-type="pmid">26461088</pub-id></element-citation></ref><ref id="B36"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egan</surname><given-names>J. M.</given-names></name></person-group><article-title>Targeting stem cells in chronic myeloid leukemia with a PPAR-<italic>&#x003b3;</italic> agonist</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2015</year><volume>373</volume><issue>20</issue><fpage>1973</fpage><lpage>1975</lpage><pub-id pub-id-type="other">2-s2.0-84946854953</pub-id><pub-id pub-id-type="doi">10.1056/NEJMcibr1511276</pub-id><pub-id pub-id-type="pmid">26559576</pub-id></element-citation></ref><ref id="B39"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Tan</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The combinatory effects of PPAR-<italic>&#x003b3;</italic> agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells</article-title><source><italic>International Journal of Molecular Medicine</italic></source><year>2014</year><volume>34</volume><issue>1</issue><fpage>262</fpage><lpage>268</lpage><pub-id pub-id-type="other">2-s2.0-84902690188</pub-id><pub-id pub-id-type="doi">10.3892/ijmm.2014.1774</pub-id><pub-id pub-id-type="pmid">24820432</pub-id></element-citation></ref><ref id="B40"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H.</given-names></name><name><surname>Nusse</surname><given-names>R.</given-names></name></person-group><article-title>Wnt/<italic>&#x003b2;</italic>-catenin signaling and disease</article-title><source><italic>Cell</italic></source><year>2012</year><volume>149</volume><issue>6</issue><fpage>1192</fpage><lpage>1205</lpage><pub-id pub-id-type="other">2-s2.0-84861986053</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2012.05.012</pub-id><pub-id pub-id-type="pmid">22682243</pub-id></element-citation></ref><ref id="B41"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>X.</given-names></name><name><surname>Xin</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name></person-group><article-title>Wnt/<italic>&#x003b2;</italic>-catenin, an oncogenic pathway targeted by H. pylori in gastric carcinogenesis</article-title><source><italic>Oncotarget </italic></source><year>2015</year><volume>6</volume><issue>34</issue><fpage>35579</fpage><lpage>35588</lpage><pub-id pub-id-type="other">2-s2.0-84946824659</pub-id><pub-id pub-id-type="doi">10.18632/oncotarget.5758</pub-id><pub-id pub-id-type="pmid">26417932</pub-id></element-citation></ref><ref id="B43"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwiatkowski</surname><given-names>A. V.</given-names></name><name><surname>Gertler</surname><given-names>F. B.</given-names></name><name><surname>Loureiro</surname><given-names>J. J.</given-names></name></person-group><article-title>Function and regulation of Ena/VASP proteins</article-title><source><italic>Trends in Cell Biology</italic></source><year>2003</year><volume>13</volume><issue>7</issue><fpage>386</fpage><lpage>392</lpage><pub-id pub-id-type="other">2-s2.0-0038094429</pub-id><pub-id pub-id-type="doi">10.1016/S0962-8924(03)00130-2</pub-id><pub-id pub-id-type="pmid">12837609</pub-id></element-citation></ref><ref id="B44"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmeyer</surname><given-names>K.</given-names></name><name><surname>Raggioli</surname><given-names>A.</given-names></name><name><surname>Rudloff</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Wnt/<italic>&#x003b2;</italic>-catenin signaling regulates telomerase in stem cells and cancer cells</article-title><source><italic>Science</italic></source><year>2012</year><volume>336</volume><issue>6088</issue><fpage>1549</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1126/science.1218370</pub-id><pub-id pub-id-type="other">2-s2.0-84862617605</pub-id><pub-id pub-id-type="pmid">22723415</pub-id></element-citation></ref><ref id="B45"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najafov</surname><given-names>A.</given-names></name><name><surname>&#x0015e;eker</surname><given-names>T.</given-names></name><name><surname>Even</surname><given-names>I.</given-names></name><etal/></person-group><article-title>MENA is a transcriptional target of the Wnt/beta-catenin pathway</article-title><source><italic>PLoS ONE</italic></source><year>2012</year><volume>7</volume><issue>5</issue><pub-id pub-id-type="other">2-s2.0-84861207252</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0037013</pub-id><pub-id pub-id-type="publisher-id">e37013</pub-id></element-citation></ref><ref id="B46"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pate</surname><given-names>K. T.</given-names></name><name><surname>Stringari</surname><given-names>C.</given-names></name><name><surname>Sprowl-Tanio</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer</article-title><source><italic>EMBO Journal</italic></source><year>2014</year><volume>33</volume><issue>13</issue><fpage>1454</fpage><lpage>1473</lpage><pub-id pub-id-type="doi">10.15252/embj.201488598</pub-id><pub-id pub-id-type="other">2-s2.0-84903702539</pub-id><pub-id pub-id-type="pmid">24825347</pub-id></element-citation></ref><ref id="B47"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecarpentier</surname><given-names>Y.</given-names></name><name><surname>Claes</surname><given-names>V.</given-names></name><name><surname>Vall&#x000e9;e</surname><given-names>A.</given-names></name><name><surname>H&#x000e9;bert</surname><given-names>J.</given-names></name></person-group><article-title>Interactions between PPAR Gamma and the Canonical Wnt/Beta-Catenin Pathway in Type 2 Diabetes and Colon Cancer</article-title><source><italic>PPAR Research</italic></source><year>2017</year><volume>2017</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1155/2017/5879090</pub-id></element-citation></ref><ref id="B49"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bignell</surname><given-names>G. R.</given-names></name><name><surname>Warren</surname><given-names>W.</given-names></name><name><surname>Seal</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Identification of the familial cylindromatosis tumor-suppressor gene</article-title><source><italic>Nature Genetics</italic></source><year>2000</year><volume>25</volume><issue>2</issue><fpage>160</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">10835629</pub-id></element-citation></ref><ref id="B50"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komander</surname><given-names>D.</given-names></name><name><surname>Reyes-Turcu</surname><given-names>F.</given-names></name><name><surname>Licchesi</surname><given-names>J. D. F.</given-names></name><name><surname>Odenwaelder</surname><given-names>P.</given-names></name><name><surname>Wilkinson</surname><given-names>K. D.</given-names></name><name><surname>Barford</surname><given-names>D.</given-names></name></person-group><article-title>Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains</article-title><source><italic>EMBO Reports</italic></source><year>2009</year><volume>10</volume><issue>5</issue><fpage>466</fpage><lpage>473</lpage><pub-id pub-id-type="other">2-s2.0-67349231313</pub-id><pub-id pub-id-type="doi">10.1038/embor.2009.55</pub-id><pub-id pub-id-type="pmid">19373254</pub-id></element-citation></ref><ref id="B51"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajan</surname><given-names>N.</given-names></name><name><surname>Ashworth</surname><given-names>A.</given-names></name></person-group><article-title>Inherited cylindromas: Lessons from a rare tumour</article-title><source><italic>The Lancet Oncology</italic></source><year>2015</year><volume>16</volume><issue>9, article no. 213</issue><fpage>e460</fpage><lpage>e469</lpage><pub-id pub-id-type="other">2-s2.0-84940533732</pub-id><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00245-4</pub-id><pub-id pub-id-type="pmid">26370355</pub-id></element-citation></ref><ref id="B53"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>A.</given-names></name><name><surname>Homey</surname><given-names>B.</given-names></name><name><surname>Soto</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Involvement of chemokine receptors in breast cancer metastasis</article-title><source><italic>Nature</italic></source><year>2001</year><volume>410</volume><issue>6824</issue><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="other">2-s2.0-0035282432</pub-id><pub-id pub-id-type="doi">10.1038/35065016</pub-id><pub-id pub-id-type="pmid">11242036</pub-id></element-citation></ref><ref id="B54"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>S.</given-names></name><name><surname>Ferrario</surname><given-names>C.</given-names></name><name><surname>Saragovi</surname><given-names>U.</given-names></name><etal/></person-group><article-title>The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer</article-title><source><italic>The American Journal of Pathology</italic></source><year>2009</year><volume>175</volume><issue>1</issue><fpage>66</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2009.080948</pub-id><pub-id pub-id-type="other">2-s2.0-67649950329</pub-id><pub-id pub-id-type="pmid">19497995</pub-id></element-citation></ref><ref id="B55"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.-J.</given-names></name><name><surname>Drakaki</surname><given-names>A.</given-names></name><name><surname>Iliopoulos</surname><given-names>D.</given-names></name><name><surname>Struhl</surname><given-names>K.</given-names></name></person-group><article-title>MiR-27b targets PPAR<italic>&#x003b3;</italic> to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells</article-title><source><italic>Oncogene</italic></source><year>2012</year><volume>31</volume><issue>33</issue><fpage>3818</fpage><lpage>3825</lpage><pub-id pub-id-type="other">2-s2.0-84865226215</pub-id><pub-id pub-id-type="doi">10.1038/onc.2011.543</pub-id><?supplied-pmid 22120719?><pub-id pub-id-type="pmid">22120719</pub-id></element-citation></ref><ref id="B56"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>K. L.</given-names></name><name><surname>Wada</surname><given-names>K.</given-names></name><name><surname>Takahashi</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells</article-title><source><italic>Cancer Research</italic></source><year>2005</year><volume>65</volume><issue>6</issue><fpage>2251</fpage><lpage>2259</lpage><pub-id pub-id-type="other">2-s2.0-20144389197</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3037</pub-id><pub-id pub-id-type="pmid">15781638</pub-id></element-citation></ref><ref id="B57"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaytseva</surname><given-names>Y. Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Southard</surname><given-names>R. C.</given-names></name><name><surname>Wallis</surname><given-names>N. K.</given-names></name><name><surname>Kilgore</surname><given-names>M. W.</given-names></name></person-group><article-title>Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells</article-title><source><italic>Molecular Cancer</italic></source><year>2008</year><volume>7, article no. 90</volume><pub-id pub-id-type="other">2-s2.0-58149528272</pub-id><pub-id pub-id-type="doi">10.1186/1476-4598-7-90</pub-id></element-citation></ref><ref id="B59"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Wong</surname><given-names>J.</given-names></name><name><surname>Conklin</surname><given-names>D. S.</given-names></name></person-group><article-title>PPAR<italic>&#x003b3;</italic> maintains ERBB2-positive breast cancer stem cells</article-title><source><italic>Oncogene</italic></source><year>2013</year><volume>32</volume><issue>49</issue><fpage>5512</fpage><lpage>5521</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.217</pub-id><pub-id pub-id-type="other">2-s2.0-84890563878</pub-id><pub-id pub-id-type="pmid">23770845</pub-id></element-citation></ref><ref id="B63"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kesanakurti</surname><given-names>D.</given-names></name><name><surname>Maddirela</surname><given-names>D.</given-names></name><name><surname>Banasavadi-Siddegowda</surname><given-names>Y. K.</given-names></name><etal/></person-group><article-title>A novel interaction of PAK4 with PPAR<italic>&#x003b3;</italic> to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in glioma</article-title><source><italic>Oncogene</italic></source><year>2017</year><volume>36</volume><issue>37</issue><fpage>5309</fpage><lpage>5320</lpage><pub-id pub-id-type="pmid">28534509</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forootan</surname><given-names>F. S.</given-names></name><name><surname>Forootan</surname><given-names>S. S.</given-names></name><name><surname>Gou</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Fatty acid activated PPAR<italic>&#x003b3;</italic> promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter</article-title><source><italic>Oncotarget</italic></source><year>2016</year><volume>7</volume><issue>8</issue><fpage>9322</fpage><lpage>9339</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.6975</pub-id><pub-id pub-id-type="other">2-s2.0-84961671408</pub-id><pub-id pub-id-type="pmid">26814431</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patitucci</surname><given-names>C.</given-names></name><name><surname>Couchy</surname><given-names>G.</given-names></name><name><surname>Bagattin</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Hepatocyte nuclear factor 1<italic>&#x003b1;</italic> suppresses steatosis-associated liver cancer by inhibiting PPAR<italic>&#x003b3;</italic> transcription</article-title><source><italic>The Journal of Clinical Investigation</italic></source><year>2017</year><volume>127</volume><issue>5</issue><fpage>1873</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.1172/JCI90327</pub-id><pub-id pub-id-type="pmid">28394260</pub-id></element-citation></ref><ref id="B58"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kourtidis</surname><given-names>A.</given-names></name><name><surname>Srinivasaiah</surname><given-names>R.</given-names></name><name><surname>Carkner</surname><given-names>R. D.</given-names></name><name><surname>Brosnan</surname><given-names>M. J.</given-names></name><name><surname>Conklin</surname><given-names>D. S.</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> protects ERBB2-positive breast cancer cells from palmitate toxicity</article-title><source><italic>Breast Cancer Research</italic></source><year>2009</year><volume>11</volume><issue>2, article R16</issue><pub-id pub-id-type="doi">10.1186/bcr2240</pub-id><pub-id pub-id-type="other">2-s2.0-68349089406</pub-id></element-citation></ref><ref id="B60"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapidot</surname><given-names>T.</given-names></name><name><surname>Sirard</surname><given-names>C.</given-names></name><name><surname>Vormoor</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A cell initiating human acute myeloid leukaemia after transplantation into SCID mice</article-title><source><italic>Nature</italic></source><year>1994</year><volume>367</volume><issue>6464</issue><fpage>645</fpage><lpage>648</lpage><pub-id pub-id-type="other">2-s2.0-0028091194</pub-id><pub-id pub-id-type="doi">10.1038/367645a0</pub-id><pub-id pub-id-type="pmid">7509044</pub-id></element-citation></ref><ref id="B61"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Hajj</surname><given-names>M.</given-names></name><name><surname>Wicha</surname><given-names>M. S.</given-names></name><name><surname>Benito-Hernandez</surname><given-names>A.</given-names></name><name><surname>Morrison</surname><given-names>S. J.</given-names></name><name><surname>Clarke</surname><given-names>M. F.</given-names></name></person-group><article-title>Prospective identification of tumorigenic breast cancer cells</article-title><source><italic>Proceedings of the National Acadamy of Sciences of the United States of America</italic></source><year>2003</year><volume>100</volume><issue>7</issue><fpage>3983</fpage><lpage>3988</lpage><pub-id pub-id-type="doi">10.1073/pnas.0530291100</pub-id><pub-id pub-id-type="other">2-s2.0-0037388204</pub-id></element-citation></ref><ref id="B62"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smalley</surname><given-names>M.</given-names></name><name><surname>Ashworth</surname><given-names>A.</given-names></name></person-group><article-title>Stem cells and breast cancer: a field in transit</article-title><source><italic>Nature Reviews Cancer</italic></source><year>2003</year><volume>3</volume><issue>11</issue><fpage>832</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1038/nrc1212</pub-id><pub-id pub-id-type="other">2-s2.0-0242667837</pub-id><pub-id pub-id-type="pmid">14668814</pub-id></element-citation></ref><ref id="B64"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craene</surname><given-names>B. D.</given-names></name><name><surname>Berx</surname><given-names>G.</given-names></name></person-group><article-title>Regulatory networks defining EMT during cancer initiation and progression</article-title><source><italic>Nature Reviews Cancer</italic></source><year>2013</year><volume>13</volume><issue>2</issue><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="other">2-s2.0-84873050284</pub-id><pub-id pub-id-type="doi">10.1038/nrc3447</pub-id><pub-id pub-id-type="pmid">23344542</pub-id></element-citation></ref><ref id="B65"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>M.</given-names></name><name><surname>Zha</surname><given-names>Y.-L.</given-names></name><etal/></person-group><article-title>PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis</article-title><source><italic>Cancer Cell</italic></source><year>2014</year><volume>26</volume><issue>3</issue><fpage>358</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.07.022</pub-id><pub-id pub-id-type="other">2-s2.0-84908666051</pub-id><pub-id pub-id-type="pmid">25203322</pub-id></element-citation></ref><ref id="B66"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamouille</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Derynck</surname><given-names>R.</given-names></name></person-group><article-title>Molecular mechanisms of epithelial-mesenchymal transition</article-title><source><italic>Nature Reviews Molecular Cell Biology</italic></source><year>2014</year><volume>15</volume><issue>3</issue><fpage>178</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1038/nrm3758</pub-id><pub-id pub-id-type="pmid">24556840</pub-id></element-citation></ref><ref id="B67"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siebzehnrubl</surname><given-names>F. A.</given-names></name><name><surname>Silver</surname><given-names>D. J.</given-names></name><name><surname>Tugertimur</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance</article-title><source><italic>EMBO Molecular Medicine</italic></source><year>2013</year><volume>5</volume><issue>8</issue><fpage>1196</fpage><lpage>1212</lpage><pub-id pub-id-type="other">2-s2.0-84881540768</pub-id><pub-id pub-id-type="doi">10.1002/emmm.201302827</pub-id><pub-id pub-id-type="pmid">23818228</pub-id></element-citation></ref><ref id="B68"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dummler</surname><given-names>B.</given-names></name><name><surname>Ohshiro</surname><given-names>K.</given-names></name><name><surname>Kumar</surname><given-names>R.</given-names></name><name><surname>Field</surname><given-names>J.</given-names></name></person-group><article-title>Pak protein kinases and their role in cancer</article-title><source><italic>Cancer Metastasis Reviews</italic></source><year>2009</year><volume>28</volume><issue>1-2</issue><fpage>51</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1007/s10555-008-9168-1</pub-id><pub-id pub-id-type="other">2-s2.0-68549126920</pub-id><pub-id pub-id-type="pmid">19165420</pub-id></element-citation></ref><ref id="B69"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radu</surname><given-names>M.</given-names></name><name><surname>Semenova</surname><given-names>G.</given-names></name><name><surname>Kosoff</surname><given-names>R.</given-names></name><name><surname>Chernoff</surname><given-names>J.</given-names></name></person-group><article-title>PAK signalling during the development and progression of cancer</article-title><source><italic>Nature Reviews Cancer</italic></source><year>2014</year><volume>14</volume><issue>1</issue><fpage>13</fpage><lpage>25</lpage><pub-id pub-id-type="other">2-s2.0-84890946972</pub-id><pub-id pub-id-type="doi">10.1038/nrc3645</pub-id><pub-id pub-id-type="pmid">24505617</pub-id></element-citation></ref><ref id="B70"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kesanakurti</surname><given-names>D.</given-names></name><name><surname>Chetty</surname><given-names>C.</given-names></name><name><surname>Rajasekhar Maddirela</surname><given-names>D.</given-names></name><name><surname>Gujrati</surname><given-names>M.</given-names></name><name><surname>Rao</surname><given-names>J. S.</given-names></name></person-group><article-title>Functional cooperativity by direct interaction between PAK4 and MMP-2 in the regulation of anoikis resistance, migration and invasion in glioma</article-title><source><italic>Cell Death &#x00026; Disease</italic></source><year>2012</year><volume>3, article e445</volume><pub-id pub-id-type="other">2-s2.0-84877592970</pub-id></element-citation></ref><ref id="B71"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siu</surname><given-names>M. K. Y.</given-names></name><name><surname>Chan</surname><given-names>H. Y.</given-names></name><name><surname>Kong</surname><given-names>D. S. H.</given-names></name><etal/></person-group><article-title>p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients</article-title><source><italic>Proceedings of the National Acadamy of Sciences of the United States of America</italic></source><year>2010</year><volume>107</volume><issue>43</issue><fpage>18622</fpage><lpage>18627</lpage><pub-id pub-id-type="other">2-s2.0-78649880786</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0907481107</pub-id></element-citation></ref><ref id="B72"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whale</surname><given-names>A. D.</given-names></name><name><surname>Dart</surname><given-names>A.</given-names></name><name><surname>Holt</surname><given-names>M.</given-names></name><name><surname>Jones</surname><given-names>G. E.</given-names></name><name><surname>Wells</surname><given-names>C. M.</given-names></name></person-group><article-title>PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity</article-title><source><italic>Oncogene</italic></source><year>2013</year><volume>32</volume><issue>16</issue><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="other">2-s2.0-84876695177</pub-id><pub-id pub-id-type="doi">10.1038/onc.2012.233</pub-id><pub-id pub-id-type="pmid">22689056</pub-id></element-citation></ref><ref id="B75"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feilchenfeldt</surname><given-names>J.</given-names></name><name><surname>Br&#x000fc;ndler</surname><given-names>M.-A.</given-names></name><name><surname>Soravia</surname><given-names>C.</given-names></name><name><surname>T&#x000f6;tsch</surname><given-names>M.</given-names></name><name><surname>Meier</surname><given-names>C. A.</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: Reduced expression of PPAR<italic>&#x003b3;</italic>-coactivator 1 (PGC-1)</article-title><source><italic>Cancer Letters</italic></source><year>2014</year><volume>203</volume><issue>1</issue><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2003.08.024</pub-id><pub-id pub-id-type="other">2-s2.0-0345167182</pub-id></element-citation></ref><ref id="B76"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname><given-names>G.</given-names></name><name><surname>Douglas-Jones</surname><given-names>A.</given-names></name><name><surname>Mansel</surname><given-names>R.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name></person-group><article-title>The localisation and reduction of nuclear staining of PPAR<italic>&#x003b3;</italic> and PGC-1 in human breast cancer</article-title><source><italic>Oncology Reports</italic></source><year>2004</year><volume>12</volume><issue>2</issue><fpage>483</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">15254719</pub-id></element-citation></ref><ref id="B78"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Barrett</surname><given-names>J. N.</given-names></name><name><surname>Moraes</surname><given-names>C. T.</given-names></name></person-group><article-title>PGC-1<italic>&#x003b1;</italic>/<italic>&#x003b2;</italic> upregulation is associated with improved oxidative phosphorylation in cells harboring nonsense mtDNA mutations</article-title><source><italic>Human Molecular Genetics</italic></source><year>2007</year><volume>16</volume><issue>8</issue><fpage>993</fpage><lpage>1005</lpage><pub-id pub-id-type="other">2-s2.0-34447338862</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddm045</pub-id><pub-id pub-id-type="pmid">17341490</pub-id></element-citation></ref><ref id="B86"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haq</surname><given-names>R.</given-names></name><name><surname>Shoag</surname><given-names>J.</given-names></name><name><surname>Andreu-Perez</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Oncogenic BRAF regulates oxidative metabolism via PGC1<italic>&#x003b1;</italic> and MITF</article-title><source><italic>Cancer Cell</italic></source><year>2013</year><volume>23</volume><issue>3</issue><fpage>302</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.02.003</pub-id><pub-id pub-id-type="other">2-s2.0-84876436850</pub-id><pub-id pub-id-type="pmid">23477830</pub-id></element-citation></ref><ref id="B94"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>K. W.</given-names></name><name><surname>Das</surname><given-names>B.</given-names></name><name><surname>Kortum</surname><given-names>R. L.</given-names></name><name><surname>Chaika</surname><given-names>O. V.</given-names></name><name><surname>Lewis</surname><given-names>R. E.</given-names></name></person-group><article-title>Kinase suppressor of ras 1 (KSR1) regulates PGC1<italic>&#x003b1;</italic> and estrogen-related receptor <italic>&#x003b1;</italic> to promote oncogenic ras-dependent anchorage-independent growth</article-title><source><italic>Molecular and Cellular Biology</italic></source><year>2011</year><volume>31</volume><issue>12</issue><fpage>2453</fpage><lpage>2461</lpage><pub-id pub-id-type="other">2-s2.0-79958035502</pub-id><pub-id pub-id-type="doi">10.1128/MCB.05255-11</pub-id><pub-id pub-id-type="pmid">21518958</pub-id></element-citation></ref><ref id="B95"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeBleu</surname><given-names>V. S.</given-names></name><name><surname>O&#x02019;Connell</surname><given-names>J. T.</given-names></name><name><surname>Herrera</surname><given-names>K. N. G.</given-names></name><etal/></person-group><article-title>PGC-1<italic>&#x003b1;</italic> mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis</article-title><source><italic>Nature Cell Biology</italic></source><year>2014</year><volume>16</volume><issue>10</issue><fpage>992</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1038/ncb3039</pub-id><pub-id pub-id-type="pmid">25241037</pub-id></element-citation></ref><ref id="B83"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBerardinis</surname><given-names>R. J.</given-names></name><name><surname>Sayed</surname><given-names>N.</given-names></name><name><surname>Ditsworth</surname><given-names>D.</given-names></name><name><surname>Thompson</surname><given-names>C. B.</given-names></name></person-group><article-title>Brick by brick: metabolism and tumor cell growth</article-title><source><italic>Current Opinion in Genetics &#x00026; Development</italic></source><year>2008</year><volume>18</volume><issue>1</issue><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2008.02.003</pub-id><pub-id pub-id-type="other">2-s2.0-43749083041</pub-id><pub-id pub-id-type="pmid">18387799</pub-id></element-citation></ref><ref id="B84"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensley</surname><given-names>C. T.</given-names></name><name><surname>Wasti</surname><given-names>A. T.</given-names></name><name><surname>DeBerardinis</surname><given-names>R. J.</given-names></name></person-group><article-title>Glutamine and cancer: cell biology, physiology, and clinical opportunities</article-title><source><italic>The Journal of Clinical Investigation</italic></source><year>2013</year><volume>123</volume><issue>9</issue><fpage>3678</fpage><lpage>3684</lpage><pub-id pub-id-type="doi">10.1172/jci69600</pub-id><pub-id pub-id-type="other">2-s2.0-84883497454</pub-id><pub-id pub-id-type="pmid">23999442</pub-id></element-citation></ref><ref id="B89"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>N.</given-names></name><name><surname>Satija</surname><given-names>Y. K.</given-names></name><name><surname>Das</surname><given-names>S.</given-names></name></person-group><article-title>PGC-1<italic>&#x003b1;</italic>, a key modulator of p53, promotes cell survival upon metabolic stress</article-title><source><italic>Molecular Cell</italic></source><year>2011</year><volume>44</volume><issue>4</issue><fpage>621</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2011.08.044</pub-id><pub-id pub-id-type="other">2-s2.0-81355153987</pub-id><pub-id pub-id-type="pmid">22099309</pub-id></element-citation></ref><ref id="B90"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Bai</surname><given-names>L.</given-names></name><etal/></person-group><article-title>RIP1 maintains DNA integrity and cell proliferation by regulating PGC-1<italic>&#x003b1;</italic>-mediated mitochondrial oxidative phosphorylation and glycolysis</article-title><source><italic>Cell Death &#x00026; Differentiation</italic></source><year>2014</year><volume>21</volume><issue>7</issue><fpage>1061</fpage><lpage>1070</lpage><pub-id pub-id-type="other">2-s2.0-84902294427</pub-id><pub-id pub-id-type="doi">10.1038/cdd.2014.25</pub-id><pub-id pub-id-type="pmid">24583643</pub-id></element-citation></ref><ref id="B91"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arany</surname><given-names>Z.</given-names></name><name><surname>Foo</surname><given-names>S.-Y.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1<italic>&#x003b1;</italic></article-title><source><italic>Nature</italic></source><year>2008</year><volume>451</volume><issue>7181</issue><fpage>1008</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1038/nature06613</pub-id><pub-id pub-id-type="other">2-s2.0-39749140405</pub-id><pub-id pub-id-type="pmid">18288196</pub-id></element-citation></ref><ref id="B92"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Hagan</surname><given-names>K. A.</given-names></name><name><surname>Cocchiglia</surname><given-names>S.</given-names></name><name><surname>Zhdanov</surname><given-names>A. V.</given-names></name><etal/></person-group><article-title>PGC-1<italic>&#x003b1;</italic> is coupled to HIF-1<italic>&#x003b1;</italic>-dependent gene expression by increasing mitochondrial oxygen consumption in skeletal muscle cells</article-title><source><italic>Proceedings of the National Acadamy of Sciences of the United States of America</italic></source><year>2009</year><volume>106</volume><issue>7</issue><fpage>2188</fpage><lpage>2193</lpage><pub-id pub-id-type="doi">10.1073/pnas.0808801106</pub-id><pub-id pub-id-type="other">2-s2.0-60549087508</pub-id></element-citation></ref><ref id="B93"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasbach</surname><given-names>K. A.</given-names></name><name><surname>Gupta</surname><given-names>R. K.</given-names></name><name><surname>Ruas</surname><given-names>J. L.</given-names></name><etal/></person-group><article-title>PGC-1<italic>&#x003b1;</italic> regulates a HIF2<italic>&#x003b1;</italic>-dependent switch in skeletal muscle fiber types</article-title><source><italic>Proceedings of the National Acadamy of Sciences of the United States of America</italic></source><year>2010</year><volume>107</volume><issue>50</issue><fpage>21866</fpage><lpage>21871</lpage><pub-id pub-id-type="other">2-s2.0-78650750309</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1016089107</pub-id></element-citation></ref><ref id="B98"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>P.</given-names></name><name><surname>Fukuda</surname><given-names>R.</given-names></name><etal/></person-group><article-title>HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity</article-title><source><italic>Cancer Cell</italic></source><year>2007</year><volume>11</volume><issue>5</issue><fpage>407</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2007.04.001</pub-id><pub-id pub-id-type="other">2-s2.0-34247614521</pub-id><pub-id pub-id-type="pmid">17482131</pub-id></element-citation></ref><ref id="B99"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaGory</surname><given-names>E.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Taniguchi</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Suppression of PGC-1<italic>&#x003b1;</italic> is critical for reprogramming oxidative metabolism in renal cell carcinoma</article-title><source><italic>Cell Reports</italic></source><year>2015</year><volume>12</volume><issue>1</issue><fpage>116</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.06.006</pub-id><pub-id pub-id-type="pmid">26119730</pub-id></element-citation></ref><ref id="B100"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simonnet</surname><given-names>H.</given-names></name><name><surname>Alazard</surname><given-names>N.</given-names></name><name><surname>Pfeiffer</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma</article-title><source><italic>Carcinogenesis</italic></source><year>2002</year><volume>23</volume><issue>5</issue><fpage>759</fpage><lpage>768</lpage><pub-id pub-id-type="other">2-s2.0-0036262039</pub-id><pub-id pub-id-type="doi">10.1093/carcin/23.5.759</pub-id><pub-id pub-id-type="pmid">12016148</pub-id></element-citation></ref><ref id="B101"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minsky</surname><given-names>N.</given-names></name><name><surname>Roeder</surname><given-names>R. G.</given-names></name></person-group><article-title>Direct link between metabolic regulation and the heat-shock response through the transcriptional regulator PGC-1<italic>&#x003b1;</italic></article-title><source><italic>Proceedings of the National Acadamy of Sciences of the United States of America</italic></source><year>2015</year><volume>112</volume><issue>42</issue><fpage>E5669</fpage><lpage>E5678</lpage><pub-id pub-id-type="other">2-s2.0-84947206622</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1516219112</pub-id></element-citation></ref><ref id="B103"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name></person-group><article-title>PGC-1<italic>&#x003b1;</italic> interacts with microRNA-217 to functionally regulate breast cancer cell proliferation</article-title><source><italic>Biomedicne &#x00026; Pharmacotherapy</italic></source><year>2017</year><fpage>541</fpage><lpage>548</lpage></element-citation></ref><ref id="B105"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piskounova</surname><given-names>E.</given-names></name><name><surname>Agathocleous</surname><given-names>M.</given-names></name><name><surname>Murphy</surname><given-names>M. M.</given-names></name><etal/></person-group><article-title>Oxidative stress inhibits distant metastasis by human melanoma cells</article-title><source><italic>Nature</italic></source><year>2015</year><volume>527</volume><issue>7577</issue><fpage>186</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/nature15726</pub-id><pub-id pub-id-type="pmid">26466563</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>C.</given-names></name><name><surname>Widlund</surname><given-names>H. R.</given-names></name><name><surname>Puigserver</surname><given-names>P.</given-names></name></person-group><article-title>PGC-1 Coactivators: Shepherding the Mitochondrial Biogenesis of Tumors</article-title><source><italic>Trends in Cancer</italic></source><year>2016</year><volume>2</volume><issue>10</issue><fpage>619</fpage><lpage>631</lpage><pub-id pub-id-type="other">2-s2.0-84991245861</pub-id><pub-id pub-id-type="doi">10.1016/j.trecan.2016.09.006</pub-id><pub-id pub-id-type="pmid">28607951</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Structure of PPAR<italic>&#x003b3;</italic> (a) and the PGC-1 family (b). (a) A/B, transcriptional activation domain; C, DNA binding domain (DBD); D, hinge region; E/F, ligand binding domain (LBD). (b) AD, transcriptional activation domain; RD, transcriptional repression domain; RS, arginine/serine rich domain; RRM, RNA binding domain.</p></caption><graphic xlink:href="PPAR2018-6727421.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Action mechanisms of PPAR<italic>&#x003b3;</italic> as a tumor suppressor. NF-<italic>&#x003ba;</italic>B, nuclear factor-<italic>&#x003ba;</italic>B; GSK-3<italic>&#x003b2;</italic>, glycogen synthase kinase 3-<italic>&#x003b2;</italic>; MUC1-C, mucin 1-C; TERT, telomerase reverse transcriptase; STAT5, signal transducer and activator of transcription factor 5; HIF-2<italic>&#x003b1;</italic>, hypoxia inducible factor-2<italic>&#x003b1;</italic>; IL-6, interleukin-6; PDK1, pyruvate dehydrogenase kinase 1.</p></caption><graphic xlink:href="PPAR2018-6727421.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Action mechanisms of PPAR<italic>&#x003b3;</italic> as a tumor promoter. ACLY, ATP citrate lyase; MIG12, midline-1-interacting G12-like protein; FASN, fatty acid synthase; NR1D1, Rev-ErbA<italic>&#x003b1;</italic>; KLF4, Kr&#x000fc;ppel-Like Factor 4; ALDH, aldehyde dehydrogenase; Nox1, NADPH oxidase 1; ROS, reactive oxygen species; VEGF, vascular endothelial growth factor.</p></caption><graphic xlink:href="PPAR2018-6727421.003"/></fig><table-wrap id="tab1" content-type="sidewaystable" orientation="portrait" position="float"><label>Table 1</label><caption><p>The role and action mechanisms of PPAR<italic>&#x003b3;</italic> as a tumor suppressor.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" rowspan="1"> Experimental system</th><th rowspan="2" align="left" colspan="1">Role and action mechanisms</th><th rowspan="2" align="center" colspan="1">References</th></tr><tr><th align="left" rowspan="1" colspan="1">Modification</th><th align="left" rowspan="1" colspan="1">Cell type</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Troglitazone treatment (PPAR<italic>&#x003b3;</italic> ligand)</td><td align="left" rowspan="1" colspan="1">Human colon cancer SW620, HCT116 cells</td><td align="left" rowspan="1" colspan="1">Inhibition of cell proliferation; induction of apoptosis; inactivation of NF-<italic>&#x003ba;</italic>B by suppression of GSK-3<italic>&#x003b2;</italic></td><td align="center" rowspan="1" colspan="1">[<xref rid="B24" ref-type="bibr">24</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PPAR<italic>&#x003b3;</italic> activation by 4-O-methylhonokiol treatment</td><td align="left" rowspan="1" colspan="1">PC3, LNCap prostate cancer cells,<break/>PC3 xenografts</td><td align="left" rowspan="1" colspan="1">Inhibition of cell proliferation and tumor growth;<break/>induction of apoptosis; p21-mediated suppression of NF-<italic>&#x003ba;</italic>B activity</td><td align="center" rowspan="1" colspan="1">[<xref rid="B25" ref-type="bibr">25</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PPAR<italic>&#x003b3;</italic> overexpression</td><td align="left" rowspan="1" colspan="1">Human colon cancer HT-29 cells</td><td align="left" rowspan="1" colspan="1">Inhibition of cell proliferation and tumor growth; ubiquitination and degradation of NF-<italic>&#x003ba;</italic>B by PPAR<italic>&#x003b3;</italic></td><td align="center" rowspan="1" colspan="1">[<xref rid="B26" ref-type="bibr">26</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PPAR<italic>&#x003b3;</italic> overexpression</td><td align="left" rowspan="1" colspan="1">Human colon cancer<break/>HT-29 cells</td><td align="left" rowspan="1" colspan="1">Inhibition of cell proliferation; ubiquitination and degradation of MUC1-C by PPAR<italic>&#x003b3;</italic></td><td align="center" rowspan="1" colspan="1">[<xref rid="B27" ref-type="bibr">27</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PPAR<italic>&#x003b3;</italic> activation by efatutazone treatment (third-generation PPAR<italic>&#x003b3;</italic> agonist)</td><td align="left" rowspan="1" colspan="1">TE-4, TE-8, TE-11,<break/>TE-6 esophageal squamous cell carcinoma (ESCC) cells; TE-4 xenografts</td><td align="left" rowspan="1" colspan="1">Inhibition of cell proliferation and tumor growth; increased p21 protein levels by inactivation of Akt</td><td align="center" rowspan="1" colspan="1">[<xref rid="B34" ref-type="bibr">28</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Pioglitazone and 6-OH-11-O-hydroxy phenanthrene (PPAR<italic>&#x003b3;</italic> and RXR agonist treatment)</td><td align="left" rowspan="1" colspan="1">Breast cancer MCF-7 cells, breast cancer associated fibroblast</td><td align="left" rowspan="1" colspan="1">Inhibition of cancer stem cell survival; inhibition of IL-6 promoter and reduced MMP-2, MMP-9 expression and activity</td><td align="center" rowspan="1" colspan="1">[<xref rid="B37" ref-type="bibr">29</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Pioglitazone treatment (PPAR<italic>&#x003b3;</italic> ligand)</td><td align="left" rowspan="1" colspan="1">Chronic myeloid<break/>leukemia cells, leukemia stem cell (LSC)</td><td align="left" rowspan="1" colspan="1">Inhibition of cancer stem cell survival; decreased expression of STAT5 and HIF-1<italic>&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1">[<xref rid="B38" ref-type="bibr">30</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PPAR<italic>&#x003b3;</italic> overexpression by PPAR<italic>&#x003b3;</italic> plasmid</td><td align="left" rowspan="1" colspan="1">Gastric cancer cell lines (MKN-28, SGC-7901, BGC-823)</td><td align="left" rowspan="1" colspan="1">Inhibition of cell proliferation and migration; downregulation of TERT and ENAH by inhibition of <italic>&#x003b2;</italic>-catenin</td><td align="center" rowspan="1" colspan="1">[<xref rid="B42" ref-type="bibr">31</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PPAR<italic>&#x003b3;</italic> activation by troglitazone, PPAR<italic>&#x003b3;</italic> siRNA transfection</td><td align="left" rowspan="1" colspan="1">Human breast cancer cell lines (MCF-7, MDA-MB-231)</td><td align="left" rowspan="1" colspan="1">Inhibition of cell proliferation; upregulation of tumor suppressor <italic>Cyld</italic></td><td align="center" rowspan="1" colspan="1">[<xref rid="B48" ref-type="bibr">32</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PPAR<italic>&#x003b3;</italic> activation by rosiglitazone, PPAR<italic>&#x003b3;</italic> inhibition by GW9662</td><td align="left" rowspan="1" colspan="1">Human breast cancer cell lines (MCF-7, MDA-MB-231)</td><td align="left" rowspan="1" colspan="1">Inhibition of cell migration and invasion; downregulation of CXCR4 gene expression</td><td align="center" rowspan="1" colspan="1">[<xref rid="B52" ref-type="bibr">33</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="tab2" content-type="sidewaystable" orientation="portrait" position="float"><label>Table 2</label><caption><p>The role and action mechanisms of PGC-1<italic>&#x003b1;</italic> in cancer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" rowspan="1"> Experimental system</th><th rowspan="2" align="left" colspan="1">Role and action mechanisms</th><th rowspan="2" align="center" colspan="1">References</th></tr><tr><th align="left" rowspan="1" colspan="1">Modification</th><th align="left" rowspan="1" colspan="1">Cell type</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>Tumor-promoting functions of PGC-1&#x003b1;</italic>
</td><td colspan="3" align="center" rowspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">PGC-1<italic>&#x003b1;</italic> knockdown</td><td align="left" rowspan="1" colspan="1">Human prostate cancer PC3, LNCap cells</td><td align="left" rowspan="1" colspan="1">Stimulation of cell proliferation; activation of androgen receptor</td><td align="center" rowspan="1" colspan="1">[<xref rid="B17" ref-type="bibr">17</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Increased PGC-1<italic>&#x003b1;</italic> expression in arsenic-induced skin cancer</td><td align="left" rowspan="1" colspan="1">Skin cancer</td><td align="left" rowspan="1" colspan="1">Stimulation of cell proliferation; enhanced mitochondrial biogenesis</td><td align="center" rowspan="1" colspan="1">[<xref rid="B79" ref-type="bibr">34</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Pgc-1&#x003b1;</italic> knockout and knockdown by lentivirus-based PGC-1<italic>&#x003b1;</italic> shRNA</td><td align="left" rowspan="1" colspan="1">Human colorectal cancer cell line (Colo205)</td><td align="left" rowspan="1" colspan="1">Stimulation of carcinogenesis and tumor growth; induction of lipogenic enzymes</td><td align="center" rowspan="1" colspan="1">[<xref rid="B80" ref-type="bibr">35</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PGC-1<italic>&#x003b1;</italic> overexpression by PGC-1<italic>&#x003b1;</italic> plasmid</td><td align="left" rowspan="1" colspan="1">Human embryonic kidney cells, human colorectal cancer SNU-C4 cells, xenograft model</td><td align="left" rowspan="1" colspan="1">Stimulation of cell proliferation and tumorigenesis; upregulation of Sp1 and ACBP; upregulation of antioxidant enzyme (catalase, SOD)</td><td align="center" rowspan="1" colspan="1">[<xref rid="B81" ref-type="bibr">36</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PGC-1<italic>&#x003b1;</italic> shRNA knockdown</td><td align="left" rowspan="1" colspan="1">Human melanoma PGC-1<italic>&#x003b1;</italic>-positive A375 cells, xenograft model</td><td align="left" rowspan="1" colspan="1">Inhibition of apoptosis; <break/>decreased ROS production, induction of ROS detoxifying enzymes</td><td align="center" rowspan="1" colspan="1">[<xref rid="B82" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Increased PGC-1<italic>&#x003b1;</italic> expression in breast cancer cell</td><td align="left" rowspan="1" colspan="1">Breast cancer cell</td><td align="left" rowspan="1" colspan="1">Stimulation of cell proliferation; enhanced glutamine-mediated lipid biosynthesis</td><td align="center" rowspan="1" colspan="1">[<xref rid="B85" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Pgc-1&#x003b1;</italic> shRNA knockdown</td><td align="left" rowspan="1" colspan="1">Human prostate cancer cell line (C4-2 cells)</td><td align="left" rowspan="1" colspan="1">Stimulation of cell proliferation; increased mitochondrial biogenesis</td><td align="center" rowspan="1" colspan="1">[<xref rid="B87" ref-type="bibr">39</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PGC-1<italic>&#x003b1;</italic> shRNA knockdown and PGC-1<italic>&#x003b1;</italic> overexpression</td><td align="left" rowspan="1" colspan="1">Human breast cancer cell, human melanoma cells</td><td align="left" rowspan="1" colspan="1">Stimulation of cell proliferation, increased invasion; increased mitochondrial biogenesis and oxidative phosphorylation</td><td align="center" rowspan="1" colspan="1">[<xref rid="B88" ref-type="bibr">40</xref>]</td></tr><tr><td colspan="4" align="left" rowspan="1">
<italic>Anticancer functions of PGC-1&#x003b1;</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">PGC-1<italic>&#x003b1;</italic> overexpression by adenovirus infection</td><td align="left" rowspan="1" colspan="1">Human ovarian cancer cell line (Ho-8910)</td><td align="left" rowspan="1" colspan="1">Induction of apoptosis; downregulation of Bcl-2 and upregulation of Bax</td><td align="center" rowspan="1" colspan="1">[<xref rid="B77" ref-type="bibr">41</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PGC-1<italic>&#x003b1;</italic> overexpression by adenovirus infection</td><td align="left" rowspan="1" colspan="1">Human hepatoma cell line (HepG2)</td><td align="left" rowspan="1" colspan="1">Inhibition of cell motility; upregulation of E-cadherin</td><td align="center" rowspan="1" colspan="1">[<xref rid="B96" ref-type="bibr">42</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PGC-1<italic>&#x003b1;</italic> overexpression</td><td align="left" rowspan="1" colspan="1">Human colorectal cancer cell lines (HT29 and HCT116)</td><td align="left" rowspan="1" colspan="1">Induction of apoptosis; ROS accumulation</td><td align="center" rowspan="1" colspan="1">[<xref rid="B97" ref-type="bibr">43</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Increased expression of PGC-1<italic>&#x003b1;</italic> by bezafibrate (PPAR panagonist)</td><td align="left" rowspan="1" colspan="1">Human cancer cell lines (HeLa, 143B, MDA-MB-231)</td><td align="left" rowspan="1" colspan="1">Inhibition of cell proliferation and invasion; increased mitochondrial biogenesis</td><td align="center" rowspan="1" colspan="1">[<xref rid="B102" ref-type="bibr">44</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PGC-1<italic>&#x003b1;</italic> overexpression</td><td align="left" rowspan="1" colspan="1">Human prostate cancer cell</td><td align="left" rowspan="1" colspan="1">Inhibition of cell proliferation and inhibition of metastasis; activation of ERR<italic>&#x003b1;</italic>-dependent transcriptional program; induction of catabolic state</td><td align="center" rowspan="1" colspan="1">[<xref rid="B104" ref-type="bibr">45</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PGC-1<italic>&#x003b1;</italic> overexpression by adenovirus infection, CRISPR-mediated PGC-1<italic>&#x003b1;</italic> depletion</td><td align="left" rowspan="1" colspan="1">Human melanoma cell</td><td align="left" rowspan="1" colspan="1">Inhibition of metastasis; inhibition of inhibitor of DNA binding protein 2 (ID2) and TCF-mediated gene transcription</td><td align="center" rowspan="1" colspan="1">[<xref rid="B106" ref-type="bibr">46</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>